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ABBREVIATIONS 
-SMA ......... -smooth muscle actin 
ACLF  .......... Acute-on-chronic liver failure 
ADAM .......... A desintegrin and metallopeptidase 
AGS ............. Alagille syndrome 
ALT  ............. Alanine aminotransferase 
AST ............. Aspartate aminotransferase 
APAP ........... Acetaminophen 
BDL ............. Bile duct ligation 
bHLH ........... Basic helix loop helix 
CADASIL ..... Subcortical infarcts and leukoencephalopathy 
CBD  ............ Common bile duct 
CCA ............. Cholangiocarcinoma 
CCl4 ............. Carbon tetrachloride 
cDNA ........... Complementary DNA 
COUP-TFII ... Chicken ovalbumin upstream promoter-transcription factor 2 
CSL ............. CBF1/Su(H)/Lag-1 
DAB  ............ Diaminobenzidine 
DEN ............. Diethylnitrosamine 
DLL .............. Delta-like ligand 
DMEM.......... Dulbecco’s Modified Eagle Medium 
DOS ............. Delta and OSM-11 
DR ............... Ductular reaction 
DSL ............. Delta-Serrate-Lag-2 
ECD  ............ Extracellular domain 
ECM............. Extracellular matrix 
EGF ............. Epidermal growth factor 
ELISA  ......... Enzyme-linked immunosorbent assay 
EMT  ............ Epithelial-mesenchymal transition 
GSI .............. γ-secretase inhibitors 
H&E ............. Hematoxylin and eosin 
HBV ............. Hepatitis B virus 
HCC ............. Hepatocellular carcinoma 
HCs.............. Hepatocytes 
HD  .............. Hetero-dimerization domain 
Hes .............. Hairy enhance of split 
Hey .............. Hairy enhancer of spit related 
HGF ............. Hepatocytes growth factor 
HNF  ............ Hepatocyte nuclear factor 
HRP  ............ Horseradish peroxidase 
HSCs ........... Hepatic stellate cells 
ICC  ............. Immunocytochemistry 
ICD  ............. Intracellular domain 
IF  ................ Immunofluorescence 
IHC .............. Immunohistochemistry 
INF-γ ............ Interferon-γ 
Irf6 ............... Interferon regulatory factor 6 
JAG.............. Jagged 
ABBREVIATIONS 
 
2 
KCs .............. Kupffer cells 
KO  .............. Knockout 
Ldlr .............. Low-density lipoprotein receptor 
LPCs ............ Liver progenitor cells 
LPS .............. Lipopolysaccharide 
LSECs  ........ Liver sinusoidal endothelial cells 
MAM ............ Mastermind complex 
MCD ............ Methionine-choline-deficient 
MDB ............ Maximum diameter of bile infarcts 
NEXT  .......... Notch extracellular truncation 
NFκB............ Nuclear factor kappa B 
NICD ............ Notch intracellular domain 
NRE ............. Notch-responsive element 
Nrf2 .............. Nuclear factor erythroid 2–related factor 2 
NRR ............. Negative regulatory region 
NTC  ............ Notch transactivation complex 
OVA  ............ Ova albumin 
PBS ............. Phosphate buffered saline 
PDAC........... Pancreatic ductal adenocarcinoma 
PDGFRB ...... Platelet derived growth factor receptor-β 
PEST ........... Proline (P), glutamic acid (E), serine (S) and threonine (T) domain 
PH ............... Partial hepatectomy 
qPCR ........... Quantitative real-time PCR 
RAM............. RBPJ-associated module 
RBPJ ......... Recombination signal binding protein J 
rCcl2  ........... Recombinant chemokine ligand 2 
rDll4 ............. Recombinant DLL4  
rJag-1  ......... Recombinant JAG1  
RT  ............... Room temperature 
SIR .............. Systemic inflammatory response syndrome 
SOX9  .......... SRY (Sex-Determining Region Y)-Box 9 
TAC ............. Transactivation complex 
TACE ........... Tumor necrosis factor α converting enzyme 
TAD ............. Transactivation domain 
T-ALL ........... T-cell acute lymphoblastic leukemia 
TGF- .......... Transforming growth factor-  
TLR  ............. Toll-like receptor 
TNF-α .......... Tumor necrosis factor-α 
TRAIL  ......... TNF-related apoptosis-inducing ligand 
Treg ............. T regulatory cells 
TSS ............. Transcription start site 
UTR  ............ Untranslated region 
VEGFR ........ Vascular endothelial growth factor receptor 
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1 INTRODUCTION 
Notch signaling is conserved among different species and mediates short-range cell-
cell communications. Notch gene was firstly discovered in Drosophila melanogaster 
in 1914 where it was responsible for notches in their wings (Lobry et al., 2014; Metz 
and Bridges, 1917). In mid-1980, the gene coding for transmembrane Notch receptor 
was cloned (Artavanis-Tsakonas et al., 1983). Subsequently, Notch family 
orthologues were identified in numerous organisms including mammals. The Notch 
signaling mediates a variety of fundamental physiological and biological processes, 
e.g., cell fate specification, organ development, cell differentiation, proliferation and
apoptosis (Fiuza and Arias, 2007; Geisler and Strazzabosco, 2015; Miele, 2006; 
Morell et al., 2013). 
1.1 Structure of Notch receptors and ligands 
In comparison to Drosophila (Drosophila melanogaster) and Nematoda 
(Caenorhabditis elegans) that have one and two Notch receptors respectively, 
mammals have four Notch receptors namely NOTCH1, 2, 3, and 4 and five canonical 
ligands called Delta-like ligand (DLL)1, 3, and 4 and Jagged (JAG)1, and 2 (Fiuza 
and Arias, 2007). Notch receptors are produced from a single protein precursor that 
is first cleaved by furin-like convertase in Golgi apparatus (S1 cleavage). This 
cleavage creates two domains: Notch extracellular domain (ECD) bound non-
covalently to transmembrane and intracellular Notch domains (NTMD, and NICD 
respectively). ECD contains 29-36 epidermal growth factor (EGF)-like repeats that 
are important in ligand binding. NTMD consists of three cysteine-rich repeat (LIN-12) 
and two hetero-dimerization units (HD) forming a negative regulatory region (NRR). 
NRR keeps the second cleavage site (S2) hidden from proteolytic enzymes until the 
receptor is activated by a Notch ligand. NICD comprises seven Ankyrin repeats, RAM 
(RBPJκ-associated module) domains, Transactivation domain (TAD) (absent in 
NOTCH3 and NOTCH4), and PEST (rich in proline (P), glutamic acid (E), serine (S), 
and threonine (T) residues) domain. RAM domain is crucial for binding to CSL 
(CBF1/Su(H)/Lag-1) DNA binding proteins and coactivators. Similarly, Notch ligands 
are heterodimer consisting of ECD and short intracellular domain (ICD) (Figure 1.1) 
(Carrieri and Dale, 2017; Gil-García and Baladrón, 2016; Kopan and Ilagan, 2009). 
ECD of Notch ligands contains DSL domain (Delta-Serrate-Lag-2). In addition, DOS 
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domain (Delta and OSM-11-like proteins) exists only in DLL1 and JAG1/2. Both of 
these domains are important for binding to EGF-like repeats of Notch receptors. 
Interestingly, Delta-like non-canonical Notch ligands (DLK1 and DLK2) do not have 
DSL domain. DLK1 and DLK2 are inhibitors of canonical Notch signaling pathway 
(Gil-García and Baladrón, 2016) which highlights the importance of DSL domain in 
the activation of Notch signaling. In comparison to DLL ligands, JAG ligands have 
specific cysteine-rich regions and more EGF-like repeats in their ECD (Blair, 2000; 
Chillakuri et al., 2012). ICD domain of Notch ligands are short and not homologous 
and contains PDZ domain (PDZ domain exists only in JAG1 and DLL1/4) which is 
necessary for binding to PDZ ligand. Noteworthy, truncated Notch ligands which 
lacks ICD function as inhibitors of Notch signaling (Hoyne, 2012).  
Figure 1.1 Structure of Notch receptors and ligands. NRR, negative regulatory region; LNR: 
LIN-12 Notch repeat; HD: hetero-dimerization units; EGF: epidermal growth factor (EGF)-like 
repeats; RAM: RBPJκ-associated module domain; ANK: Ankyrin repeats; TAD: 
Transactivation domain; PEST: rich in proline (P), glutamic acid (E), serine (S), and threonine 
(T) residues domain; DSL: Delta-Serrate-Lag-2; DOS: Delta and OSM-11-like proteins. N 
and C represent the amino- and carboxy-terminus of the protein. Modified from Kopan and 
Ilagan, 2009.  
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1.2 Mechanism of canonical Notch signaling 
Canonical Notch signaling starts with the binding of a Notch ligand to a Notch 
receptor expressed on neighboring cells. This kind of binding is called TRANS 
activation. In contrary, when Notch ligands and receptors expressed on the same 
cells, their binding can lead to Notch inhibition instead of activation. The later type of 
binding is described as CIS inhibition (del Álamo et al., 2011). The TRANS binding 
facilitates uncovering S2 cleavage site and makes it susceptible to proteolytic 
cleavage by a disintegrin and metallopeptidase (ADAM10/17). S2 cleavage 
generates Notch extracellular truncation (NEXT) which is rapidly cleaved by 
transmembrane γ-secretase enzyme complex (S3) using presenilin catalytic subunit. 
S3 cleavage releases NICD, which translocates into the nucleus where it binds to 
RBPJk (also known as CSL, CBF1/Su(H)/Lag-1) displacing corepressors and 
attracting coactivators as histone acetylase P300 and Mastermind complex (MAM) 
forming together Notch transactivation complex (NTC) (Figure 1.2). Noteworthy, 
RBPJk binds to a unique sequence in DNA (CGTGGGAA) which is known as Notch-
responsive element (NRE) and exists in the promoters of different Notch target genes 
(Tun et al., 1994). After transmitting the signal, NICD is quickly phosphorylated at 
PEST domain followed by ubiquitinylation and degradation (Kopan and Ilagan, 2009). 
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viral proteins such as adenovirus 13SE1A or Epstein-Barr Virus EBNA2 could form 
TAC with RBPJk and stimulate Notch target genes (Siebel and Lendahl, 2017).  
1.4 Notch target genes: 
The best-characterized Notch target genes are Hes (Hairy enhance of split) and Hey 
(Hairy enhancer of spit related) proteins which belong to basic helix loop helix (bHLH) 
family and act as transcription repressors (Fischer and Gessler, 2007). In addition, 
Notch signals induce other genes involved in A) cells proliferation, e.g. cyclin D 
(Joshi et al., 2009), and Myc (Krejcí et al., 2009), B) apoptosis and cell cycle arrest, 
e.g. Bcl-2 (Deftos et al., 1998) and p21 (Rangarajan et al., 2001), C) Notch pathway 
itself creating a positive and negative feedback loop to control its activity, e.g. Nrarp 
and Numb (Krejcí et al., 2009) and D) other signaling pathways that facilitate cross-
talking, e.g. Lip1 and NfκB (Krejcí et al., 2009; Osipo et al., 2008). The output of the 
Notch signaling is highly context-dependent. 
1.5 Regulation of Notch signaling 
To achieve optimal activity, Notch signaling is regulated by different mechanisms 
including I) Positive and negative feedback loops. Expression of Notch ligands, e.g. 
DLL1, and JAG1 and receptors, e.g. NOTCH1, and NOTCH3, are controlled by 
Notch signaling. The increase of ligands and receptors augment Notch signaling, 
thus creating a positive feedback loop. In additional conditions, Notch ligands could 
negatively regulate Notch signaling through binding Notch receptors expressed on 
the same cells, which is defined as “CIS” inhibition. Moreover, ICD of JAG1 can 
inhibit Notch activity through promoting the degradation of NICD. Alternatively, the 
classical Notch target genes Hes1 and Hey1 are transcriptional repressors that 
suppress the transcription of several Notch genes (Borggrefe and Liefke, 2012). II) 
microRNAs (miRNAs)-mediated regulation. miRNAs are short non-coding nucleotide 
sequences that bind 3´- untranslated region (UTR) region of specific mRNAs leading 
to their degradation (Cech and Steitz, 2014). Through targeting several members of 
Notch family, miRNA-34a mimics induce cell cycle arrest in a rat model of partial 
hepatectomy (PH) (Wang et al., 2017). Also, miRNA-30 targets Dll4 expression 
during angiogenesis leading to enhanced sprouting and branching of blood vessels 
(Rostama et al., 2014).  III) rapid degradation of NICD is also a basic regulatory 
mechanism to keep Notch signal transient. After transporting the Notch signal to the 
nucleus, CycC:CDK8 enzyme phosphorylate the PEST and TAD domains of NICD, 
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which is followed by degradation by Fbw7/Sel10 ubiquitin ligase (Fryer et al., 2004). 
These diverse mechanisms might explain why small alterations in Notch signaling 
create complex biological outcomes. 
1.6 Expression of Notch ligands and receptors in the liver 
Different Notch receptors (Nijjar et al., 2001) are expressed in distinct liver cells in a 
healthy liver. NOTCH1 and 2 are mainly expressed in cholangiocytes and liver 
progenitor cells (LPCs) (Morell et al., 2013). NOTCH3 and 4 are expressed in 
mesenchymal and endothelial cells of the liver (Morell et al., 2013). Liver injury alters 
the expression of Notch receptors. For example, quiescent hepatic stellate cells 
(qHSCs) express mainly NOTCH1 and low levels of NOTCH3 (Morell et al., 2013). 
During transactivation process, NOTCH1 is downregulated while NOTCH3 is 
upregulated (Chen et al., 2012; Sawitza et al., 2009). NOTCH1 and 2 are 
upregulated in cholangiocytes during a biliary injury (Boulter et al., 2012a). These 
results suggest a potential role of distinct NOTCH receptors in different liver 
diseases. 
JAG1 and DLL4 are main Notch ligands expressed in the liver. JAG1 localize in 
biliary cells, liver progenitor cells (LPCs) and smooth muscle cells of the portal vein 
(Hofmann et al., 2010; Spee et al., 2010), while DLL4 expression is limited to 
endothelial cells (Loomes et al., 2002).   
1.7 Notch signaling in development 
Notch signaling plays central roles in tissue and organ development, i.e. stem cell 
maintenance and differentiation. Lateral inhibition is a specific differentiation program 
in which Notch signaling can specify two different cell populations from identical 
parent cell population. Notch signaling can keep the balance between these cellular 
fates. These processes are important in the development of many organs such as 
skeletal muscle, lung, nervous system, cardiac tissue, pancreas, and liver (Siebel 
and Lendahl, 2017).  
1.7.1 Notch signaling in liver development: 
Mutations of JAG1 in patients with Alagille syndrome (AGS) gave the first evidence of 
the involvement of Notch signaling in liver development (Li et al., 1997). AGS is a 
multi-organ disorder characterized by ductopenia in the liver (Morell et al., 2013). 
Subsequent studies showed the importance of Notch signaling in stimulating 
INTRODUCTION 
9 
bipotential hepatoblasts to commit biliary cell fate and to express biliary-specific 
markers such as hepatocyte nuclear factor (HNF)-1β and SRY (Sex-Determining 
Region Y)-Box (SOX)9 (Morell et al., 2013; Zong et al., 2009). The role of Notch 
signaling in the morphogenesis of intrahepatic bile duct was elegantly confirmed by 
knockout (KO) mouse models of different components of Notch pathway, e.g. Hes1 
(Kodama et al., 2004), Rbpjκ (Sparks et al., 2010), Notch1, Notch2 (Geisler et al., 
2008; Morell et al., 2013). 
1.8 Notch signaling in diseases 
Several genetic disorders caused by gene mutations of Notch signaling pathway due 
to its central roles in the development of various organs (Aster et al., 2017; Mašek 
and Andersson, 2017). Mutations in NOTCH3 cause subcortical infarcts and 
leukoencephalopathy (CADASIL), a hereditary condition characterized by stroke and 
dementia (Joutel et al., 1996). Similarly, infantile myofibromatosis is caused by 
mutations in Platelet Derived Growth Factor Receptor beta (PDGFRB) and NOTCH3, 
which lead to the development of tumors in skin, bone, muscle, and viscera 
(Martignetti et al., 2013). Other genetic disorders caused by mutations in Notch 
genes were summarized in Table 1.1.   
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Table 1.1 Genetic disorders caused by mutations in Notch-related genes. Modified 
from Aster et al., 2017; Mašek and Andersson, 2017. 
Genetic Disorder Mutated 
Gene(s) 
Involved Organs References 
subcortical infarcts 
and leukoencephalopathy 
(CADASIL) 
NOTCH3 cerebral arteries Joutel et al., 
1996 
Alagille syndrome (AGS) JAG1 
NOTCH2 
cardiac tissues, 
liver, and bone 
McDaniell et al., 
2006; Oda et 
al., 1997 
Spondylocostal 
dysostosis (Levin 
syndrome) 
DLL3 Vertebrae and ribs Bulman et al., 
2000 
Aortic valve disease NOTCH1 Heart Garg et al., 
2005 
Adams-Oliver syndrome DLL4 
NOTCH1 
RBPJk 
Skull and limbs Hassed et al., 
2012; Meester 
et al., 2015; 
Southgate et 
al., 2015 
Hajdu-Cheney syndrome NOTCH2 Bone tissue Simpson et al., 
2011 
Infantile Myofibromatosis NOTCH3 Tumors in multiple 
organs 
Martignetti et 
al., 2013 
Furthermore, Notch signaling is active in adult diseases, e.g. cancer (Aster et al., 
2017), inflammation and injury (Geisler and Strazzabosco, 2015; Morell and 
Strazzabosco, 2014; Morell et al., 2013), fibrosis (Chen et al., 2012), metabolic 
disorders (Geisler and Strazzabosco, 2015), and others (Siebel and Lendahl, 2017).  
The role of Notch signaling in different types of cancers received special attention 
due to its evident role in controlling cell cycle and cellular proliferation. In fact, Notch 
signaling plays complex roles in cancer, which could be oncogenic, a tumor 
suppressor, or both (Nowell and Radtke, 2017) (Table 1.2). Although the exact 
underlying mechanisms remain to be elucidated, oncogenic mechanisms were 
related to the ability of Notch pathway to activate genes of cell growth such as Myc 
(Palomero et al., 2006) and PI3K-Akt (Palomero et al., 2007) and cell survival as 
Nfκb (Shin et al., 2006; Vacca et al., 2006). On the other hand, Notch can suppress 
tumors by mediating antigrowth and pro-differentiation effects through controlling cell 
INTRODUCTION 
11 
cycle regulator p21 (Rangarajan et al., 2001), or interferon regulatory factor (Irf) 6 
(Restivo et al., 2011).  
Table 1.2 Tumor promoting and suppressive role of Notch pathway in cancer. 
Modified from Giovannini et al., 2016; Lobry et al., 2011.
Cancer Involved 
Notch R 
Role References 
T-cell acute 
lymphoblastic 
leukemia (T-ALL) 
NOTCH1 Weng et al., 2004 
Skin tumors NOTCH1 Nicolas et al., 2003 
Squamous cell 
carcinomas 
NOTCH1 Zhang et al., 2016a 
Forebrain tumor NOTCH1 
NOTCH2 
Giachino et al., 2015 
pancreatic ductal 
adenocarcinoma 
(PDAC) 
NOTCH1 
NOTCH2 
Hanlon et al., 2010; Mazur et 
al., 2010 
Gastric cancer NOTCH2 Tseng et al., 2012 
Colorectal cancer NOTCH1 Ishiguro et al., 2017 
Breast cancer NOTCH1 
NOTCH2 
NOTCH3 
NOTCH4 
Fu et al., 2010; Gallahan and 
Callahan, 1997; Klinakis et 
al., 2006; Yamaguchi et al., 
2008 
Ovarian cancer NOTCH3 Park et al., 2006 
Prostate cancer NOTCH1 Ye et al., 2012 
Bladder cancer NOTCH2 Hayashi et al., 2016 
Hepatocellular 
carcinoma (HCC) 
NOTCH1 
NOTCH2 
NOTCH3 
Giovannini et al., 2013, 
2016b 
Cholangiocarcinoma 
(CCA) 
NOTCH1 Huntzicker et al., 2015 
    Tumor suppressive   Oncogenic 
1.8.1 Notch signaling in liver cancer 
The mutation of Notch genes in liver cancer was not yet demonstrated; however,  
there are many reports showing the dysregulation of Notch signaling in liver 
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carcinogenesis (Geisler and Strazzabosco, 2015). For example, NOTCH1 and 
NOTCH2 mediate oncogenic role in hepatocellular carcinoma (HCC) and 
cholangiocarcinoma (CCA). The overexpression of N1ICD and N2ICD in 
hepatoblasts induces HCC and CCA formation in mice (Dill et al., 2013; Villanueva et 
al., 2012). In the presence of tumor-inducing agents such as diethylnitrosamine 
(DEN), or thioacetamide, tumor formation shifts mainly to CCA (Dill et al., 2013; 
Sekiya and Suzuki, 2012). Several studies reported as well oncogenic role for 
NOTCH3 in HCC and CCA (Guest et al., 2014; Hu et al., 2013). However, NOTCH3 
inhibition did not influence tumor burden in mice (Huntzicker et al., 2015). 
Furthermore, DLL4 ligand regulates tumor angiogenesis. Interestingly, the activation 
and the inhibition of DLL4-mediated Notch signaling inhibit tumor growth by inducing 
tumor hypoxia (Noguera-Troise et al., 2006; Segarra et al., 2008).  
Tumor suppressive roles have been attributed as well to Notch signaling in liver 
malignancies. For example, NOTCH1 sensitizes HCC cells to TNF-related apoptosis-
inducing ligand (TRAIL)-induced apoptosis by interfering with the proteasomal 
degradation of p53 (Wang et al., 2009).  
1.8.2 Notch signaling in liver regeneration 
The effects of Notch signaling on liver injury and regeneration were extensively 
investigated in acute and chronic liver diseases. Köhler et al. reported nuclear 
accumulation of NICD in hepatocytes of rats 15 minutes (min) following PH (Köhler et 
al., 2004). In addition, silencing of Jag1 and Notch1 significantly reduced the 
proliferative capacity of hepatocytes of animals receiving PH (Köhler et al., 2004). 
Notch signaling exerts its effect in liver regeneration in cooperation with numerous 
growth factors such as hepatocytes growth factor (HGF) and EGF, and cytokines 
such as tumor necrosis factor (TNF)-α, and tumor growth factor (TGF)-β (Best et al., 
2015).  
The regenerative capacity of the liver is unique, by which a rodent liver can restore 
lost mass in 7 days (d) after 70% PH (Libbrecht, 2006).  Regeneration in a healthy 
liver mainly depends on hepatocytes replication. In patients with chronic or severe 
liver diseases, regeneration occurs in the presence of continuous injuring insult such 
as virus and toxic drugs. Upon loss of more than 50% hepatocytes, the regenerative 
capacity of hepatocytes is compromised. In this situation, liver progenitors cells 
(LPCs)-based regeneration initiates (Best et al., 2015; Katoonizadeh et al., 2006).  
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LPCs are bi-potential liver stem cells localizing inside the canal of Herring and able to 
differentiate into hepatocytes or cholangiocytes (Lukacs-Kornek and Lammert, 2017). 
Microenvironment surrounding LPCs orchestrates the direction of their differentiation 
exploiting Notch and Wnt signaling. After the biliary injury, JAG1 expressed on 
myofibroblasts activates LPCs to differentiate to cholangiocytes (Boulter et al., 
2012a). On the other side, when hepatocytes are the main damaged cells, infiltrated 
macrophages release WNT3A upon phagocytosis of the dead hepatocytes. WNT3A 
is a ligand of Wnt signaling pathway, which inhibits Notch signaling in LPCs by 
upregulating NUMB protein. Inhibition of Notch signaling stimulates the differentiation 
of LPCs to hepatocytes (Boulter et al., 2012b; Strazzabosco and Fabris, 2013). 
These results suggest that Notch signaling is the default inducer of biliary 
differentiation. In line with these results, the inhibition of Notch signaling by γ-
secretase inhibitors (GSI) decreases the number of LPCs and ductular reaction (DR) 
in mice models with experimentally-induced biliary damage (Fiorotto et al., 2013). 
Noteworthy, this attractive idea could not be confirmed in a later study of lineage 
tracing. Both genetic inhibition of Notch signaling and activation of Wnt signaling 
were required for effective biliary maturation and expansion of DR, but failed to 
instruct the cells of 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-induced DR to 
differentiate to hepatocytes (Jörs et al., 2015).  
Beside the role of Notch signaling in liver regeneration, it could protect liver cells by 
upregulating Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) signaling pathway. The 
protective functions of Nrf2 signaling are linked to its ability to stimulate the synthesis 
of various antioxidant enzymes that defense against oxidative stress-mediated 
cellular toxicity (Nguyen et al., 2009). Wakabayashi et al. reported that transient and 
stable expression of NICD in mouse hepatocytes protects the liver against 
paracetamol (APAP)-induced hepatotoxicity by inducing Nrf2 expression. 
(Wakabayashi et al., 2014). In summary, Notch can cross-talk with different signaling 
pathways to direct liver regeneration or afford cytoprotection. 
1.8.3 Notch signaling and liver fibrosis 
Liver fibrosis is a scarring healing response characterized by the production of a 
large amount of extracellular matrix (ECM) which disturbs the normal function of the 
liver and could progress to liver cirrhosis and cancer in advanced stages (Friedman, 
2008; Hernandez-Gea and Friedman, 2011).  
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Notch signaling plays crucial roles in the fibrosis of various organs such as liver, 
kidney, peritoneum, and heart (Bielesz et al., 2010; Chen et al., 2012; Nistri et al., 
2017; Zhu et al., 2010). HSCs, the main producer of ECM in the liver, upregulate 
NOTCH3 and JAG1 during activation and trans-differentiation to myofibroblasts 
(Chen et al., 2012). Incubation of primary stellate cells with profibrogenic cytokine 
TGF-β induces Jag1 expression (Morell et al., 2017), whereas HSCs stimulated with 
JAG1 increases -smooth muscle actin (α-SMA) and collagen production (Geisler 
and Strazzabosco, 2015). 
In vivo inhibition of Notch signaling with GSI protected hepatocytes against apoptosis 
and improved liver fibrosis in rats or mice with carbon tetrachloride (CCl4) (Bansal et 
al., 2015; Chen et al., 2012), bile duct ligation (BDL) (Zhang et al., 2016b), and 
methionine-choline-deficient (MCD) diet administration (Morell et al., 2017).  
In patients, Notch signaling is activated in severe liver fibrosis caused by different 
etiologies (He et al., 2015). On the other hand, AGS patients rarely develop liver 
fibrosis (Fabris et al., 2007). Taken together, Notch signaling might mediate 
profibrogenic functions in the liver.  
1.8.4 Notch signaling and inflammation 
Notch pathway can modulate inflammatory responses by stimulating M1 polarization 
of macrophages, which represent the inflammatory subtype of macrophage 
population (Xu et al., 2012). Thus, inhibition of Notch signaling suppressed M1 
macrophage, increased anti-inflammatory M2 macrophage, and prevented HSC 
activation (Bansal et al., 2015). Notch1 heterozygous KO mice have a reduced 
inflammatory response to lipopolysaccharide (LPS) and interferon (INF)-γ treatments 
(Outtz et al., 2010). 
 In vitro, the incubation of RAW264.7 macrophage cell line with LPS and INF-γ 
increased the expression of NOTCH1 and JAG1 (Monsalve et al., 2006), whereas 
N1ICD overexpression increased TNF-α and IL-6 expression (Shang et al., 2016) 
suggesting a positive feedback loop between inflammation and Notch signaling. 
Several reports showed the interdependence between inflammation and liver fibrosis. 
For example, HSCs are highly responsive to LPS and inflammatory cytokines. 
Furthermore, secreted inflammatory cytokines keep the activated state of HSCs and 
maintain their survival (Seki and Schwabe, 2015). Additionally, targeting hepatic 
inflammation could stabilize and reverse liver fibrosis (Czaja, 2014). Considering its 
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roles in liver inflammation and fibrosis, Notch signaling might be a promising 
therapeutic target in inflammation-driven liver fibrosis. 
1.9 JAG1- versus DLL4-mediated pathobiological effects 
DLL4 and JAG1 are two Notch ligands expressed in the liver. Although both Notch 
ligands share similar binding sites, they mediate distinct biological functions. The 
molecular mechanisms remain obscure. In certain scenarios, it might be related to 
the expression pattern of such ligands on different cellular compartments. In other 
cases, the opposite biological functions are because of the differential affinity of 
Notch receptors to those ligands. 
In asthma for example, DLL4 and JAG1 can produce opposite effects. JAG1 
expressed on bone marrow-derived dendritic cells (DCs) activate Notch receptors on 
CD4+ T-Cells stimulating IL-4 production and lead to airway hyper-responsiveness. 
On the other hand, DLL4 expressed on regulatory T cells (Treg) cells decreased the 
number of lung vessels which improved airway hyper-responsiveness (Huang et al., 
2009; Okamoto et al., 2009). Recently, these results were confirmed in animal model 
of ova albumin (OVA)-induced allergic asthma (Huang et al., 2017). Moreover, 
upregulated Jag1 facilitated fibrogenesis, whereas Dll4 was downregulated in an 
animal model of bleomycin-induced pulmonary fibrosis (Yin et al., 2017). 
During angiogenesis, DLL4- and JAG1-mediated effects antagonize each other. 
NOTCH1-DLL4 mediated signaling inhibits the sprouting of endothelial tip cells. JAG1 
antagonizes DLL4-mediated effects mainly because of posttranslational modification 
of NOTCH1 receptor by Fringe enzyme. The Fringe-modified NOTCH1 receptor has 
a higher affinity for DLL4 than JAG1. When both ligands expressed on the same 
cells, JAG1 interfere with binding of DLL4 to NOTCH1 receptor and enhances 
sprouting. Furthermore, DLL4 reduce vascular endothelial growth factor receptor 
(VEGFR)2 while JAG1 induce VEGFR3 expression (Benedito et al., 2009; Liu et al., 
2014). Recently, vimentin, an intermediate filament protein, was reported to balance 
JAG1 and DLL4 signaling in angiogenesis. Vimentin enhances JAG1 mediated 
signaling by supporting ligand-receptor trans-endocytosis, while it decreased DLL4 
mediated signaling through inhibition of expression of Fringe proteins (Antfolk et al., 
2017).  
In the liver, DLL4 and JAG1 differentially regulate chicken ovalbumin upstream 
promoter-transcription factor 2 (COUP-TFII), an orphan nuclear receptor involved in 
HSCs activation and trans-differentiation. Fibrotic human and mouse liver have high 
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expression of COUP-TFII. In cultured HSCs, JAG1, but not DLL4, suppress COUP-
TFII in Hey1-dependent mechanisms (Ceni et al., 2017).  
In addition, inflammatory cytokines differentially regulate DLL4 and JAG1 expression. 
In primary macrophages, IFN-γ augmented LPS-induced JAG1 expression, whereas 
it downregulated DLL4 (Foldi et al., 2010). TNF-α induced JAG1, but not DLL4 
expression in mouse aortic endothelial cells (Nus et al., 2016). 
1.10 The aim of the current study: 
Although Notch signaling plays crucial roles in liver injury and fibrosis, the 
contribution of individual Notch ligands is still not well-defined. The current knowledge 
of Notch signaling in liver fibrosis is based mainly on animal models receiving GSI 
administration. GSI have several side effects including gastrointestinal toxicity 
because of the vital role of Notch signaling in gastrointestinal hemostasis. 
Furthermore, the γ-secretase enzyme impacts expression of other important 
molecules such as CD44, cadherins, and ERBB4 (Andersson and Lendahl, 2014). 
These effects result in non-Notch signaling-dependent biological responses. To avoid 
these side effects, the current study investigates the effects of DLL4 and JAG1 on 
liver damage in patients with hepatitis B virus (HBV)-induced liver cirrhosis, and two 
mouse models induced by CCl4 and BDL, respectively. In addition, how DLL4 and 
JAG1 exert their effects was investigated in isolated primary liver cells and cell lines. 
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2 MATERIALS AND METHODS 
2.1 Reagents 
The reagents, chemicals, cytokines, recombinant proteins, and antibodies used in the 
current study were listed in Table 2.1 and Table 2.2. 
Table 2.1 Reagents 
Reagent Order Nr. Company 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic 
acid 
(HEPES) 
H4034-100G Sigma-Aldrich, Munich, 
Germany 
5x HOT FIREPol EvaGreen 
qPCR Mix Plus (ROX) 
08-24-00020 Solis Biodyne, Tartu, 
Estonia 
Acid Fuchsin F8129-25G Sigma-Aldrich, Munich, 
Germany 
Acrylamide/Bis-acrylamide, 
30% solution 
10688.02 SERVA, Heidelberg, 
Germany 
Agar 5210.1 Carl Roth, Mannheim, 
Germany 
Ammonium persulfate 
(APS) 
A3678-25G Sigma-Aldrich, Munich, 
Germany 
Bouin’s solution HT10132-1L Sigma-Aldrich, Munich, 
Germany 
Bovine Serum Albumin 
(BSA) 
11930 SERVA, Heidelberg, 
Germany 
Bromophenol blue APP3640A/0.005 Armin Baack, Schwerin, 
Germany 
Calcium chloride dihydrate 
(CaCl2.2 H2O) 
C3306-500G Sigma-Aldrich, Munich, 
Germany 
CD11b MicroBeads, human 
and mouse 
130-049-60 Miltenyi, Gladbach, 
Germany 
CHAPS 1479.3 Carl Roth, Mannheim, 
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Germany 
Collagen 11 179 179 001 Roche, Mannheim, 
Germany 
Collagenase type II, CLSII C2-22 Merck, New Jersey, USA 
complete protease inhibitor 
cocktail tablets 
4693132001 Roche, Mannheim, 
Germany 
Dako Dual Endogenous 
Enzyme Block 
S200389-2 DAKO, Glostrup, Denmark 
DAKO Fluorescent 
Mounting Medium 
S3023 DAKO, Glostrup, Denmark 
DAPI D9542-5MG Sigma-Aldrich, Munich, 
Germany 
Deoxycholic acid sodium 
salt (DOC) 
18330.03 SERVA, Heidelberg, 
Germany 
Dexamethasone D1159-100MG Sigma-Aldrich, Munich, 
Germany 
D-Glucose G8270-1KG Sigma-Aldrich, Munich, 
Germany 
Direct Red 80 (sirius red) 365548-5G Sigma-Aldrich, Munich, 
Germany 
Dithiothreitol (DTT) A1101,0010 AppliChem, Darmstadt, 
Germany 
DMEM medium BE12-709F/12-M Lonza, Basel, Switzerland 
DMEM/F-12 21331-020 Thermo Fischer Scientific, 
Massachusetts, USA 
DNase I A3778 AppliChem, Darmstadt, 
Germany 
dNTP Mix, 10 mM each, 0.2 
mL 
R0191 Thermo Fischer Scientific, 
Massachusetts, USA 
DPBS 9124.1 Carl Roth, Mannheim, 
Germany 
DRAQ5 4084L New England Biolabs, 
Massachusetts, USA 
Easycoll L6145 Merck, New Jersey, USA 
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Eosin 1098441000 Merck, New Jersey, USA 
Ethanol 99% T171.4 Carl Roth, Mannheim, 
Germany 
Ethanol absolute LC40451 neoLab, Heidelberg, 
Germany 
Ethylene glycol-bis(β-
aminoethyl ether)-N,N,N',N'-
tetraacetic acid (EGTA) 
E3889-25G Sigma-Aldrich, Munich, 
Germany 
Ethylenediaminetetraacetic 
acid 
(EDTA) 
324503 Calbiochem, San Diego, 
USA 
Fetal Bovine Serum (FBS) 10270 Thermo Fischer Scientific, 
Massachusetts, USA 
Glycerol G5516-500ml Sigma-Aldrich, Munich, 
Germany 
Hanks' BSS (1X) 882012 Biozym, Oldendorf, 
Germany 
Hematoxylin solution A 
according to Weigert 
X906.1 Carl Roth, Mannheim, 
Germany 
Hematoxylin solution 
according to Meyer 
MHS16-500ML Sigma-Aldrich, Munich, 
Germany 
Hematoxylin solution B 
according to Weigert 
X907.1 Carl Roth, Mannheim, 
Germany 
HiSpeed Plasmid Midi Kit 
(25) 
12643 Qiagen, Hilden, Germany 
Histodenz D2158-100G Sigma-Aldrich, Munich, 
Germany 
Human recombinant DLL4 1506-D4-050-CF R&D, Minneapolis, USA 
Human recombinant JAG1 1277-JG R&D, Minneapolis, USA 
Hydrogen peroxide (H2O2) 1072102500 Merck, New Jersey, USA 
Insulin-Transferrin-Selenium 
(ITS -G) (100X) 
41400045 Thermo Fischer Scientific, 
Massachusetts, USA 
JSH-23 (NfκB inhibitor) J4455-5MG Sigma-Aldrich, Munich, 
Germany 
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Ketaminhydrochlorid 
 100  mg / ml 
Hostaket ® Parke-Davis, Freiburg, 
Germany 
L-Alanine A7627-100G Sigma-Aldrich, Munich, 
Germany 
L-Asparagine A0884-25G Sigma-Aldrich, Munich, 
Germany 
L-Aspartic Acid A6558-25G Sigma-Aldrich, Munich, 
Germany 
LB Broth (Miller) X968.1 Carl Roth, Mannheim, 
Germany 
L-Citrullin C7629-25G Sigma-Aldrich, Munich, 
Germany 
L-Cysteine 168149-25G Sigma-Aldrich, Munich, 
Germany 
L-Glutamic Acid G1251-100G Sigma-Aldrich, Munich, 
Germany 
L-Glutamine G3126-100G Sigma-Aldrich, Munich, 
Germany 
L-Glutamine 200mM G7513 Sigma-Aldrich, Munich, 
Germany 
L-Glycine G7126-100G Sigma-Aldrich, Munich, 
Germany 
L-Histidine H-6034 Sigma-Aldrich, Munich, 
Germany 
Light green L5382-10G Sigma-Aldrich, Munich, 
Germany 
Lipopolysaccharide (LPS) L3012-5mg Sigma-Aldrich, Munich, 
Germany 
L-Isoleucine I7403-25G Sigma-Aldrich, Munich, 
Germany 
L-Leucine L-8912 Sigma-Aldrich, Munich, 
Germany 
L-Lysine L5501-25G Sigma-Aldrich, Munich, 
Germany 
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L-Methionine M9625-25G Sigma-Aldrich, Munich, 
Germany 
L-Ornithine O6503-25G Sigma-Aldrich, Munich, 
Germany 
L-Phenylalanine P2126-100G Sigma-Aldrich, Munich, 
Germany 
L-Proline P-5607 Sigma-Aldrich, Munich, 
Germany 
L-Serine S4311-25G Sigma-Aldrich, Munich, 
Germany 
L-Threonine T8625-25G Sigma-Aldrich, Munich, 
Germany 
L-Tryptophane T8941-25G Sigma-Aldrich, Munich, 
Germany 
L-Tyrosine T3754-50G Sigma-Aldrich, Munich, 
Germany 
Luciferase assay reagent E1483 Promega, Mannheim, 
Germany 
Luminol 09253-25G Sigma-Aldrich, Munich, 
Germany 
L-Valine V0513-25G Sigma-Aldrich, Munich, 
Germany 
Magnesium Chloride, 
Hexahydrate (MgCl2. 6H2O) 
5980-500GM Sigma-Aldrich, Munich, 
Germany 
Magnesium sulfate 
heptahydrate (MgSO4 .7 
H2O) 
63138-250G Sigma-Aldrich, Munich, 
Germany 
Malinol oil 3c-242 Waldeck, Münster, 
Germany 
Methanol 4627.2 Carl Roth, Mannheim, 
Germany 
Mouse CCL2/JE/MCP-1 
DuoSet ELISA kit 
DY479-05 R&D, Minneapolis, USA 
Mouse recombinant CCL2 479-JE-010 R&D, Minneapolis, USA 
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Mouse recombinant DLL4 1389-D4-050-CF R&D, Minneapolis, USA 
N,N,N′,N′-
Tetramethylethylenediamine 
(TEMED) 
T9281-25ML Sigma-Aldrich, Munich, 
Germany 
Nonidet P40 11754599001 Sigma-Aldrich, Munich, 
Germany 
Nycodenz 1002424 Progen Biotechnik, 
Heidelberg, Germany 
Page Ruler Plus (prestained 
protein ladder) 
26620 Thermo Fischer Scientific, 
Massachusetts, USA 
p-Coumaric Acid C9008-5G Sigma-Aldrich, Munich, 
Germany 
Penicillin-Streptomycin 100x 
(P/S) 
P0781 Sigma-Aldrich, Munich, 
Germany 
Percoll GEHE17-0891-01 Sigma-Aldrich, Munich, 
Germany 
Phosphatase inhibitors 
cocktail 
P5726 Sigma-Aldrich, Munich, 
Germany 
Phosphate buffer saline 
(PBS) powder  
L182-50 Merck, New Jersey, USA 
Phosphomolybdic acid 4440.3 Carl Roth, Mannheim, 
Germany 
Phosphotungstic acid 
hydrate 
2635.2 Carl Roth, Mannheim, 
Germany 
Ponceau Xylidine P2395-25G Sigma-Aldrich, Munich, 
Germany 
Potassium chloride (KCl) P9333-500G Sigma-Aldrich, Munich, 
Germany 
Potassium phosphate 
dibasic (KH2PO4) 
P2222-100G Sigma-Aldrich, Munich, 
Germany 
Pronase E 1.07433.005 Merck, New Jersey, USA 
Proteinase K S300402-2 DAKO, Glostrup, Denmak 
Random Hexamer EA SO142 Thermo Fischer Scientific, 
Massachusetts, USA 
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Recombinant Human 
CCL2/MCP-1 
279-MC-010 R&D, Minneapolis, USA 
Recombinant murine TNF-α 315-01A Peprotech, Hamburg, 
Germany 
Reporter Lysis Buffer 5X E3971 Promega, Mannheim, 
Germany 
RevertAid H Minus Reverse 
Transcriptase 
EP0451 Thermo Fischer Scientific, 
Massachusetts, USA 
RNA extraction kit 1060100300 Stratec, Birkenfeld, 
Germany 
Roti Histofix (4% buffered 
formaldehyde solution) 
5666.2 Carl Roth, Mannheim, 
Germany 
Saturated aqueous solution 
of picric acid (1.3% in H2O) 
P6744-1GA Sigma-Aldrich, Munich, 
Germany 
Sodium bicarbonate 
(NaHCO3) 
S5761-500G Sigma-Aldrich, Munich, 
Germany 
Sodium chloride (NaCl) P029.3 Carl Roth, Mannheim, 
Germany 
Sodium dodecyl sulfate 
(SDS) 
2326.2 Carl Roth, Mannheim, 
Germany 
Sodium phosphate dibasic 
(Na2HPO4) 
255793-10G Sigma-Aldrich, Munich, 
Germany 
Sodium phosphate 
monobasic monohydrate 
(NaH2PO4. H2O) 
71507-250G Sigma-Aldrich, Munich, 
Germany 
Subcloning Efficiency™ 
DH5α™ Competent Cells 
18265017 Thermo Fischer Scientific, 
Massachusetts, USA 
Sucrose S0389-500G Sigma-Aldrich, Munich, 
Germany 
TGF-β 240-B-010 R&D, Minneapolis, USA 
TRIS 5429.5 Carl Roth, Mannheim, 
Germany 
Trisodium citrate dihydrate S1804-500G Sigma-Aldrich, Munich, 
Germany 
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Triton X-100 T-9284 Sigma-Aldrich, Munich, 
Germany 
Trypsin-EDTA solution 10X T4174-100M Sigma-Aldrich, Munich, 
Germany 
Tween 20 1247ML500 neoLab, Heidelberg, 
Germany 
Viromer red VR-01LB-01 Lipocalyx, Halle, Germany 
William’s E medium W1878-6X500ML Sigma-Aldrich, Munich, 
Germany 
Xylazine hydrochloride 
20 mg / ml 
Rompun ® Bayer, Leverkusen, 
Germany 
Xylene 9713.2 Carl Roth, Mannheim, 
Germany 
β-Mercaptoethanol A4338,0250 AppliChem, Darmstadt, 
Germany 
Table 2.2 Primary and secondary antibodies used in the current study. * antigen 
retrieval with citrate buffer. For antigen retrieval without *, EDTA buffer was used. 
Antibody name Host Product 
number 
Dilution Application Company 
Primary antibodies 
-SMA mouse M0851 1:500 IHC/IF DAKO 
Ccl-2 rabbit LS-
C211039-
100 
1:200 IHC LS-Bio 
CD16 mouse Ab74512 Ready 
to use 
IF Abcam 
CD45 rabbit ab10558 1:50 IHC* Abcam 
Cleaved-
caspase-3 
rabbit 9664 1:100 IHC* Cell Signaling 
Desmin rabbit ab15200 1:100 IF Abcam 
Dll1 rabbit sc-9102 1:100 IHC Santa Cruz 
Dll3 rabbit sc-67269 1:100 IHC Santa Cruz 
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Dll4 rabbit sc-28915 1:100 IHC Santa Cruz 
F4/80 rat ab6640 1:150 IHC* Abcam 
F4/80 rat 14-4801-81 1:100 IF eBioscience 
GAPDH rabbit Ab9485 1:2500 WB Abcam 
Histone H1 mouse Sc-8030 1:500 WB Santa Cruz 
HNF-4α rabbit 3113 1:100 IF Cell signaling 
Jagged1 goat sc-6011 1:500 IHC Santa Cruz 
Jagged2 rabbit sc-5604 1:50 IHC Santa Cruz 
Ly-6B rat MCA771GA 1000 IHC * AbD Serotec 
Myeloperoxidase rabbit AB45977 1:50 IHC * Abcam 
Notch1 goat sc-6014 1:100 IHC Santa Cruz 
Notch2 rabbit ab8926 1:200 IHC Abcam 
Notch3 rabbit sc-5593 1:100 IHC Santa Cruz 
Notch4 rabbit ab23427 1:50 IHC Abcam 
p50 mouse Sc-8414 1:500 WB Santa Cruz 
p65 rabbit Sc-372 1:500 WB Santa Cruz 
Stabilin2 mouse MAB3645 1:25 IF R & D 
Secondary antibodies 
Polyclonal anti-
Rabbit / HRP 
swine P0217 1:200 IHC Dako 
Polyclonal anti-
mouse / HRP 
goat P0447 1:200 IHC Dako 
Polyclonal Anti-
Rat / HRP 
rabbit P0450 1:200 IHC Dako 
Alexa Fluor® 
488 Anti-Rat 
Donkey 712-546-
150 
1:200 IF Jackson 
ImmunoResearch 
Alexa Fluor® 
488  Anti-Rabbit 
Donkey 711-546-
152 
1:200 IF Jackson 
ImmunoResearch 
Alexa Fluor® 
488 Anti-Mouse 
Donkey 715-545-
150 
1:200 IF Jackson 
ImmunoResearch 
Cy™ Anti-Mouse Donkey 715-225-
150 
1:200 IF Jackson 
ImmunoResearch 
Cy™2 Anti- Donkey 711-225- 1:200 IF Jackson 
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Rabbit 152 ImmunoResearch 
Cy™2 Anti-Rat Donkey 712-225-
153 
1:200 IF Jackson 
ImmunoResearch 
Cy™3 Anti-Rat Donkey 712-165-
153 
1:200 IF Jackson 
ImmunoResearch 
Cy™3 Anti-
Mouse 
Donkey 715-165-
150 
1:200 IF Jackson 
ImmunoResearch 
Cy™3 Anti-
Rabbit 
Donkey 711-165-
152 
1:200 IF Jackson 
ImmunoResearch 
Anti-Mouse / 
HRP 
goat sc-2063 1:3000 WB Santa Cruz 
Anti-Rabbit / 
HRP 
goat sc-2301 1:3000 WB Santa Cruz 
2.2 Patients’ liver tissue specimen 
Liver tissues from 31 patients, 5 with hepatolithiasis, and 26 with HBV-induced 
cirrhosis ( 10 with compensated cirrhosis and 16 with acute-on-chronic liver failure 
(ACLF)) were obtained from The First Affiliated Hospital, College of Medicine, 
Zhejiang University, China. In addition, 5 liver samples from patients undergoing liver 
resection due to hepatic hemangioma were included as a healthy control. Informed 
written consents were collected from all patients or relatives. The study was 
approved by the Ethics Committee of The First Affiliated Hospital, College of 
Medicine, Zhejiang University. 
2.3 Cells 
Primary mouse liver cells, e.g. hepatocytes (HCs), Kupffer cells (KCs), and hepatic 
stellate cells (HSCs) and cell lines, e.g. mouse HSCs (JS-1), mouse HCs (AML-12), 
and mouse macrophage (RAW264.7) were used in the current study. JS-1 cell line 
(Guo et al., 2010) was kindly provided by Dr. Scott Friedman (Mount Sinai School of 
Medicine, New York, USA). RAW264.7 cells were a kind gift from Dr. Astrid 
Schmieder (Heidelberg University, Germany). AML-12 cell line was purchased from 
ATCC cell bank (Virginia, USA). Cells were cultured in described mediums (Table 
10.1) in a humidified incubator at 37 C° with 5% CO2. 
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2.3.1 Isolation and treatment of primary HSCs: 
HSCs were isolated according to Mederacke et al., 2015 with minor modifications. 
Briefly, 5-7 months old C57BL/6N mice were anesthetized with a commercial 
combination of xylazine and ketamine (Hostaket ® and Rompun ®), the liver was 
exposed and perfused through vena cava with three different sequential solutions: 
EGTA, pronase E, and collagenase D (Appendix 10.1.7.14). Next, the portal vein was 
cut to drain out the perfusion solutions and to reduce the internal liver pressure. 
Later, the liver was minced gently, and filtered through 100 µM cell strainer (Corning, 
Wiesbaden, Germany). Finally, HSCs were separated from the top layer of Nycodenz 
gradient (8.27%). After three days of culture with TGF-β (5 ng/ml) and/or recombinant 
Dll4 (rDll4) (500 ng/ml), the RNA was collected for analysis of HSC activation 
markers, e.g. α-Sma, collagen 1α1 (Col1α1), and collagen 1α2 (Col1α2). 
2.3.2 Isolation and treatment of primary HCs and KCs: 
Isolation of mouse HCs and KCs were carried out according to Hengstler et al., 2000; 
and Hu et al., 2014 with minor modifications. Similar to HSCs isolation, 16 weeks old 
C57BL/6N were anesthetized and the liver was exposed and perfused sequentially 
through vena cava with EDTA and collagenase solutions. Next, the liver was minced 
gently in suspension buffer and filtered through 100 µM cell strainer (Corning, 
Wiesbaden, Germany). Hepatocytes were separated by centrifugation at 50g for 2 
min. The viable HCs were enriched by percoll density gradient and used for activated 
caspase-3 assay. KCs were isolated from non-parenchymal cell fraction using CD11b 
microbeads according to Hu et al., 2014. KCs were cultured in KC medium and 
stimulated with LPS (20 ng/ml) for 16 hours (h). Then, the cells were incubated with 
LPS for 6 h with/without rDll4 (500 ng/ml). RNA was collected for further analysis. All 
used buffers and mediums were described in Appendix 10.2 and 10.1.7. The purity of 
isolated primary HCs, KCs, and HSCs was checked by immunofluorescence staining 
with specific cell markers, hepatocyte nuclear factor (HNF)-4α, F4/80, and DESMIN 
respectively (Figure 2.1). 
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2.5 Histological and immune-histological analysis: 
Liver tissues were fixed in 4% paraformaldehyde and embedded in paraffin. Later, 
the tissues were sectioned at 4 µm and used for staining. 
2.5.1 Histology: 
Liver tissues were deparaffinized in a series of xylene and ethanol solutions 
respectively. After deparaffinization, the tissues were stained for hematoxylin and 
eosin (H&E), sirius red, and Masson's trichrome as described below. 
A. H&E staining: 
We followed the protocol of Fischer et al. (2008) with minor modifications. 
Briefly, deparaffinized slides were stained with Meyer’s modified hematoxylin 
for 3 min followed by washing in cold H2O for 10 min. Excess hematoxylin was 
removed by washing the slides in 0.1% HCl (diluted in 70% ethanol) for 5 
seconds. After washing the slides in warm H2O for 10 min, the slides were 
incubated with eosin for 3 min. Finally, the slides were washed with tap water 
for 2 min, dehydrated by passing through series of ethanol and xylene 
solutions respectively, mounted with resinous oil, covered, and left for drying. 
B. Sirius red staining: 
Deparaffinized slides were incubated with picro-sirius red solution for 20 min at 
room temperature (RT). Then, the slides were washed twice with absolute 
ethanol, mounted and covered (Junqueira et al., 1979). The solutions were 
described in Appendix 10.1.1.3. 
C. Masson's trichrome staining: 
Deparaffinized slides were fixed in Bouin's Solution to improve staining quality. 
Then, nuclei were stained with Weigert's iron hematoxylin solution. After a 
wash in distilled water, the slides were incubated in solution A for 10 min, 
solution B for 5 min, and solution C for 10 min respectively. Finally, the slides 
were dehydrated and mounted as previously described. The used solutions 
were described in Appendix 10.1.1.4. Detailed procedure was described by 
Bancroft and Layton, 2013. 
2.5.2 Immunohistochemistry (IHC) staining: 
IHC protocol was used as previously described by Weng et al., 2009. After paraffin 
removal, the slides were washed by distilled water and antigens are unmasked by 
heating the sample at 99 C° in EDTA buffer (0.1 mM, pH=8.4) or citrate buffer (10 
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mM, pH=6) for 10 min (Table 2.2). After cooling the slides to RT, the slides are 
washed 3 times with PBS and incubated with DAKO dual peroxidase blocker for 20 
min at RT to block endogenous peroxidase activity. Then, the slides were washed 3 
times with PBS and the tissues were incubated with primary antibody at 4 C° 
overnight (Table 2.2). Next day, slides were washed 3 times with PBS to remove 
excess primary antibody and incubated with horseradish peroxidase (HRP)-labelled 
secondary antibody (Table 2.2) for 30 min at RT. After washing 3 times in PBS, the 
brown color was developed by incubating the slide with HRP substrate, 
diaminobenzidine (DAB), for less than 10 min. Then, nuclei were counterstained with 
Meyer`s modified hematoxylin. Lastly, the slides were dehydrated, mounted, and left 
for drying. Later, the staining was analyzed by Leica microscope (Leica Microsystem, 
Wetzlar, Germany). For quantification purposes, pictures were taken from at least 
five non-overlapping fields (100x) per slide and analyzed by ImageJ software version 
1.50b (NIH, Maryland, USA). Tissue sections treated only with secondary antibodies 
were used as a negative control. 
2.5.3 Immunofluorescence (IF) staining: 
We followed the same protocol as IHC except that slides were incubated with 
fluorescent-labeled secondary antibodies for 1 h at RT (Table 2.2). After washing in 
PBS, the nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI) 
(1:3000) or DRAQ5® (1:1000) for 5 min at RT. Finally, the tissues were covered with 
fluorescent mounting medium (DAKO) and examined under Leica confocal 
microscope TCS SP8 (Leica Microsystem, Wetzlar, Germany). Tissue sections 
without primary antibodies were used as a negative control. This protocol was 
modified from Weng et al., 2009.  
2.5.4 Immunocytochemistry (ICC): 
The protocol of Abcam (Cambridge, UK) was followed with minor modifications. 
Initially, RAW264.7 cells were grown on coverslips at 2x105 cells per well in 12-well 
plate overnight. Then, cells were incubated with LPS (1000 ng/ml) with/without rDll4 
(500 ng/ml), or rJag-1 (500 ng/ml) for 25 min in starvation medium. Afterward, the 
cells were washed twice with PBS and fixed in 4% buffered formaldehyde solution for 
15 min at RT. Then, the cells were washed twice in wash buffer and incubated with 
blocking buffer for 45 min at RT. After removal of the blocking buffer, the cells were 
incubated with primary antibodies following the previously described IF protocol. The 
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wash and blocking buffers were described in Appendix 10.1.2.3 and 10.1.2.4 
respectively. 
2.6 RNA isolation, and quantitative real-time PCR (qPCR) 
After treatment, the cells were washed twice with Hanks’ balanced salt solution 
(Hanks’BSS) (Biozym, Oldendorf, Germany), and were lysed by lysis solution TR 
containing β-Mercaptoethanol (1%) as RNase inhibitor. Total RNA was extracted 
according to manufacturer’s protocol (Stratec, Birkenfeld, Germany). Briefly, DNA 
was removed using a DNA-binding spin filter. Then, the binding properties of RNA 
were optimized by adding 70% ethanol. Next, RNA was bound to RTA spin filter and 
washed one time with wash buffer R1 and twice with R2. Finally, RNA was eluted 
with elution buffer R and stored immediately on ice. RNA concentration was 
determined by measuring the absorbance of isolated RNA at λ=260 nm (A260). The 
ratio between A260 and A280 estimated the purity of RNA. Next, 500 ng RNA was 
converted into complementary DNA (cDNA) with RevertAid H Minus Reverse 
Transcriptase (Thermo Fischer Scientific, Massachusetts, USA). cDNA was used for 
qPCR following the instructions of EvaGreen qPCR Mix (Solis Biodyne, Tartu, 
Estonia). The transcripts number in each sample was quantified in triplicate. The 
sequences of primers were described in Table 2.3. For data analysis, the 2-∆Ct 
method was used (Schmittgen and Livak, 2008).  
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Table 2.3 Primers used for qPCR 
Gene Forward sequence Reverse sequence 
-actin 5'-GTGCTATGTTGCTCTAGACTTCG-3' 5'-ATGCCACAGGATTCCATACC-3' 
-Sma 5'-GGACGTACAACTGGTATTGTGC-3' 5'-CGGCAGTAGTCACGAAGGAAT-3' 
Ccl-2 5'-CTTCTGGGCCTGCTGTTCA-3' 5'-CAGCCTACTCATTGGGATCA-3' 
Ccl5 5'-AGATCTCTGCAGCTGCCCTCA-3' 5'-GGAGCACTTGCTGCTGGTGTAG-3' 
Ccl8 5'-TCTACGCAGTGCTTCTTTGCC-3' 5'-AAGGGGGATCTTCAGCTTTAGTA-3' 
Col1a1 5'-CATGTTCAGCTTTGTGGACCT-3' 5'-GCAGCTGACTTCAGGGATGT-3' 
Col1a2 5'-AAGGGTGCTACTGGACTCCC-3' 5'-TTGTTACCGGATTCTCCTTTGG-3' 
Cxcl10 5'-AAATCATCCCTGCGAGCCTATC-3' 5'-GGAGCCCTTTTAGACCTTTTTTGG-3' 
Cxcl9 5'-TGGGCAGAAGTTCCGTCTTG-3' 5'-ATTACCGAAGGGAGGTGGACAACG-3' 
Hes1 5'-AGAAGAGGCGAAGGGCAAGAAT-3' 5'-AGGTCATGGCGTTGATCTGG-3' 
Hes5 5'-CGCATCAACAGCAGCATAGAG-3' 5'-TGGAAGTGGTAAAGCAGCTTC-3' 
Il-1 5'-CGAAGACTACAGTTCTGCCATT-3' 5'-GACGTTTCAGAGGTTCTCAGAG-3' 
Il-10 5'-TCTTTCAAACAAAGGACCAGC-3' 5'-ACCCAGGGAATTCAAATGC-3' 
Il-6 5'-CTGCAAGAGACTTCCATCCAG-3' 5'-AGTGGTATAGACAGGTCTGTTGG-3' 
ppia 5’-GAGCTGTTTGCAGACAAAGTT-3’ 5’-CCCTGGCACATGAATCCTGG-3’ 
Tgf- 5'-GCAACAACGCCATCTATGAG-3' 5'-ACGCCAGGAATTGTTGCTAT-3' 
Tnf- 5'-CTGAACTTCGGGGTGATCG-3' 5'-GGCTACAGGCTTGTCACTCG-3' 
2.7 Subcellular fractionation and Immunoblot analysis 
RAW264.7 cells were seeded at 2x106 cells per well in 6-well plate overnight. Then, 
cells were incubated with LPS (1000 ng/ml) with/without rDll4 (500 ng/ml), or rJag-1 
(500 ng/ml) for 25 min in starvation medium. Afterward, the cellular lysate was 
fractionated according to GeneTex’s instructions (Irvine, USA). 
2.7.1 Subcellular fractionation: 
The cells were washed twice with cold PBS and scrapped in 1 ml PBS/1 mM EDTA 
solution. Then, the cells were pelleted and lysed using Harvest Buffer containing a 
cocktail of proteases and phosphatases inhibitors. After centrifugation, the 
supernatant contained cytoplasmic/membrane proteins while the pellet had nuclear 
proteins. The pellets were washed several times with Buffer A and were loosen by 
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Buffer C. After centrifugation, nuclear protein was collected from the supernatant. 
The used buffers were described in Appendix 10.1.4. 
2.7.2 Immunoblot analysis: 
After subcellular fractionation, the protein concentration was measured using DC 
protein assay (Bio-Rad, Munich, Germany). Then, the protein in SDS-containing 
loading buffer (4X) was denatured by heating at 90 C° for 10 min. Twenty µg per 
sample were separated using polyacrylamide gel (12%). After electrophoresis, 
protein was transferred to nitrocellulose membrane (Pierce, Rockford, IL) and 
blocked with 5% milk solution in Tris-buffered saline with Tween 20 (TBST) buffer for 
1 h at RT. Next, the membrane was incubated with primary antibodies at 4 C° 
overnight. In the second day, non-bound primary antibodies were removed by 
washing with TBST buffer and the membrane was incubated with HRP-conjugated 
secondary antibody (Santa Cruz) for 1 h at RT (Table 2.2). The membrane was 
developed using enhanced chemiluminescence (ECL) solution. GAPDH (Abcam, 
Cambridge, UK) and Histone H1 (Santa Cruz, Heidelberg, Germany) were used as 
internal loading control for cytoplasmic and nuclear fraction, respectively. The density 
of bands was quantified using ImageJ software version 1.50b (NIH, Maryland, USA). 
The composition of gel and buffers were described in Appendix 10.1.5. This protocol 
was done following Mahmood and Yang, 2012 with minor modifications. 
2.8 Luciferase assay and plasmid transfection: 
 Ccl2 promoter reporter ampicillin-resistant plasmid (pcDNA3.1-CCL2-Luc) was kindly 
provided by Dr. Sze-Kwan Lin (National Taiwan University Hospital, Taipei, Taiwan) 
(Kok et al., 2009). The pcDNA3.1-CCL2-Luc construct was amplified in DH5α™ 
Competent Cells (Thermo Fischer Scientific, Massachusetts, USA) and extracted 
following HiSpeed Plasmid Midi Kit instructions (Qiagen, Hilden, Germany). The 
construct contains 540-bp of the mouse Ccl2 promoter starting from 20-bp 
downstream of transcription start site (TSS) linked to luciferase reporter enzyme. For 
measuring luciferase activity, RAW264.7 cells were seeded at 5 x 105 cells per well in 
6-well plate. After reaching 80-90% confluency, the cells were transfected with 
pcDNA3.1-CCL2-Luc construct using Viromer red (Lipocalyx, Halle, Germany) 
according to manufacturer’s instructions. After 4 h, the medium was replaced with 
serum-free medium. Next day, the cells were treated with LPS (20 ng/ml) or 
LPS+rDll4 (500 ng/ml). Six hours later, the cells were lysed with reporter lysis buffer 
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(5X) (Promega, Mannheim, Germany). Firefly luciferase activity was measured by 
adding 50 µl firefly luciferase substrate from Promega into 30 µl cellular lysate in 96-
well white plate and measuring luminescence using Tecan infinite M200 microplate 
reader (Thermo Scientific, Waltham, MA, USA). The activity of firefly luciferase was 
normalized to protein concentration of each sample. 
2.9 Enzyme-linked Immunosorbent Assay (ELISA): 
RAW264.7 cells were seeded at 2 x 105 cells per well in 12-well plate. Then, cells 
were treated with LPS (20 ng/ml) for 16 h before they received rDll4 (500 ng/ml) for 6 
h. CCL2 concentration in the culture supernatant was determined using Mouse
CCL2/JE/MCP-1 DuoSet ELISA kit following the manufacturer’s instructions (R&D, 
Minneapolis, MN). Briefly, 96-well microplate (R&D Systems, order # DY990) were 
covered with 100 µl anti-Ccl2 capture antibody overnight at RT. After washing with 
wash buffer, each well was covered with 300 µl diluent buffer for 1 h at RT. Then, 
plate wash was repeated, 100 µl of diluted standard (seven point 2-fold serial dilution 
starting from 3.91 pg/ml to 250 pg/ml) and diluted supernatant were added in 
duplicate, and incubated for 2 h at RT. Afterward, 100 µl anti-Ccl2 biotinylated goat 
anti-mouse detection antibody was added after plate washing and incubated for 
additional 2 h at RT. Then, 100 µl Streptavidin-HRP was added and the plate is 
sealed and incubated for 20 min at RT in the dark. The color was developed by 
adding 100 µl substrate tetramethylbenzidine (Abcam, ab171529) for 20 min and 
stopped by 100 µl stop acidic solution (Abcam, ab171529). Absorbance was 
measured at λ=450 nm using Tecan infinite M200 microplate reader (Thermo 
Scientific, Waltham, MA, USA). Absorbance at λ=540 nm was used to correct for 
optical imperfections in the plate. The average absorbance value of the standard was 
plotted against the concentration (pg/ml) using four-parameter logistic (4-PL) curve-fit 
created by Excel software (Windows office, 2010). The concentration of the diluted 
supernatants was determined from the curve and multiplied by the dilution factor to 
determine the original concentration of CCL2. Buffers were described in Appendix 
10.1.3. 
2.10 Activated caspase-3 assay: 
The activity of caspase-3 enzyme was determined fluorometrically as previously 
described with minor modifications (Murillo et al., 2005). The principle of the assay 
depends on the specific proteolytic cleavage of a cell-permeable fluorogenic 
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substrate N-Acetyl-Asp-Glu-Val-Asp-7-amido-4-Trifluoromethylcoumarin (AC-DEVD-
AFC, Biomol) by activated caspase-3, which release free fluorescent 7-amino-4-
trifluoromethylcoumarin (AFC) with an excitation wavelength at λ=400 nm and an 
emission wavelength at λ=505 nm that correlates with the amount of activated 
caspase-3 in the cellular extract. Primary hepatocytes were seeded at 150,000 
cells/well in the collagen-coated 12-well plate and were treated with TGF-β (5 ng/ml) 
or TNF-α (20 ng/ml) with/without rDll4 (500 ng/ml) or rJag-1 (500 ng/ml) at 37 C° in 
medium 3 (Table 10.1). After 24 h, the cells were washed with Hank’s BSS solution 
and were lysed with lysis buffer (Appendix 10.1.6). Protein concentration was 
determined using DC protein assay (Bio-Rad, Munich, Germany).  The reaction was 
set up in white 96-well flat-bottom plate by adding 70 µl assay buffer (Appendix 
10.1.6), 20 µl cell extract, and 10 µl AC-DEVD-AFC (diluted 1:20 in assay buffer with 
a final concentration of 0.05 mg/ml). After incubation for 60 min at 37 C° in the dark, 
the fluorescence was measured with Tecan infinite M200 microplate reader (Thermo 
Scientific, Waltham, MA, USA). Blank values were subtracted from the measured 
fluorescence values and the obtained values were normalized to protein content of 
each sample. 
2.11 Statistics 
Results were presented as mean ± standard error of the mean (SEM) unless 
specially indicated. Two-tailed unpaired Student t-test was used to analyze 
parametric data. Survival data were analyzed using Kaplan-Meier method and 
Mantel-Cox-Log rank test. Statistical analyses were performed mainly using 
GraphPad Prism version 6.0 for Windows (GraphPad Software Inc). Probability value 
(P-value) < 0.05 was considered significant and depicted graphically as one or more 
stars depending on its value (*P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001). 
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3 RESULTS 
3.1 In vivo investigation of DLL4 
3.1.1 Expression of Notch family members in patients’ livers 
Twenty liver tissue specimens (10 from patients with HBV-related cirrhosis, 5 with 
hepatolithiasis, and 5 controls with hemangioma) were used to perform IHC for 
detecting the expression of Notch receptors (NOTCH1, NOTCH2, NOTCH3, and 
NOTCH4) and ligands (DLL1, DLL3, DLL4, JAG1, and JAG2). Except JAG1 
expressed in cholangiocytes, no additional Notch family members were detectable by 
IHC in control liver tissues (Table 3.1). Neither Notch ligands nor receptors were 
detected in sinusoidal cells of hepatolithiasis patients (Table 3.1). However, JAG1, 
DLL4, and NOTCH1 expressed in sinusoidal cells of patients with cirrhosis (Figure 
3.1). 
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Table 3.1 Expression of Notch ligands and receptors in patients with HBV-associated 
cirrhosis, hepatolithiasis, and hepatic hemangioma. 
Protein Liver cells Hemangioma 
(n=5) 
Hepatolithiasis 
(n=5) 
Cirrhosis 
(n=10) 
JAG1 Hepatocytes - - - 
Cholangiocytes + (5) + (5) + (10) 
Sinusoidal cells - - + (8) 
JAG2 Hepatocytes - - - 
Cholangiocytes - - - 
Sinusoidal cells - - - 
DLL1 Hepatocytes - - - 
Cholangiocytes - - - 
Sinusoidal cells - - - 
DLL3 Hepatocytes - - + (4) 
Cholangiocytes - - - 
Sinusoidal cells - - - 
DLL4 Hepatocytes - - - 
Cholangiocytes - - - 
Sinusoidal cells - - + (4) 
NOTCH1 Hepatocytes - - - 
Cholangiocytes - + (5) + (7) 
Sinusoidal cells - - + (5) 
NOTCH2 Hepatocytes - - - 
Cholangiocytes - + (5) + (10) 
Sinusoidal cells - - - 
NOTCH3 Hepatocytes - - + (6) 
Cholangiocytes - - + (8) 
Sinusoidal cells - - - 
NOTCH4 Hepatocytes - - + (3) 
Cholangiocytes - - + (6) 
Sinusoidal cells - - - 
(): number of positive samples 
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patients, DLL4 positive sinusoidal cells did not express CD68 but were CD16 positive 
(Figure 3.2 C and D). These results suggest that DLL4 expressed in KCs and/or 
LSECs of different patients.  
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Figure 3.2 Co-staining for (A) DLL4 and -SMA, (B-C) DLL4 and CD68 and (D) DLL4 and 
CD16 were performed in representative patients.  
3.1.3 rDll4 administration improved liver fibrosis in CCl4-challenged mice 
Next, effects of rDll4 were examined in 2 animal models of liver injury i) 
hepatotoxicant model induced by CCl4 injection and ii) cholestasis-driven model by 
BDL. In the CCl4 animal model, treatment of mice with rDll4 increased Hes1 and 
Hes5 mRNA expression (Figure 3.3 A), indicating active Notch signal following rDll4 
administration. IHC for α-SMA and sirius red staining showed that rDll4 treatment 
significantly decreased CCl4-induced α-SMA expression and collagen deposition 
(Figure 3.3 B and C). rDll4 alone had no significant effects on α-SMA and collagen 
deposition (Figure 3.3 C). 
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3.1.4 rDll4 decreased inflammatory cells infiltration and hepatocyte apoptosis in 
CCl4-challenged mice 
Liver fibrosis is usually accompanied by inflammation and hepatocellular death (Malhi 
and Gores, 2008). Therefore, the effects of rDll4 on liver inflammation were 
investigated by H&E staining and IHC staining for F4/80 and CD45, markers of 
macrophages and leukocytes, respectively. rDll4 administration significantly 
decreased the recruitment of inflammatory cell to livers after CCl4 challenge (Figure 
3.4 A and B). Furthermore, rDll4 significantly reduced mRNA levels of inflammatory 
cytokines (e.g. Tnf-α, Il-6, and Inf-γ) and chemokines (e.g. Ccl-2, Ccl-5, and Cxcl-9) 
(Figure 3.4 C and D). In addition, hepatocyte apoptosis was measured by IHC for 
cleaved-caspase-3. rDll4 reduced CCl4-induced hepatocytes death (Figure 3.4 A and 
B). 
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3.1.7  DLL4 expression was inversely correlated with CCL2 
Next, we investigated the expression of CCL2 and DLL4 in 26 liver samples from 
patients with chronic HBV infection (16 with ACLF and 10 with cirrhosis). All ACLF 
samples showed a strong CCL2 immuno-reactivity whereas DLL4 expression was 
negative. In cirrhotic samples, 4 patients with quiescent cirrhosis did not have both 
DLL4 and CCL2 expression. In 6 patients with active cirrhosis, 4 had DLL4 positive, 
and CCL2 negative cells, whereas 2 had liver cells with negative DLL4, but positive 
CCL2 expression (Table 3.2 and Figure 3.11) 
Table 3.2 DLL4 and CCL2 expression in 26 patients with chronic HBV infection. 
Sixteen patients with ACLF and 10 with cirrhosis (four with quiescent cirrhosis and 6 
with active cirrhosis). 
Diseases Inflammatory 
grade 
DLL4 CCL2 
quiescent cirrhosis 0 - - 
(n=4) 0 - - 
0 - - 
0 - - 
Active cirrhosis 2 + - 
(n=6) 2 + - 
2 + - 
3 + - 
3 - + 
3 - + 
ACLF 3 - + 
(n=16) 3 - + 
3 - + 
3 - + 
3 - + 
3 - + 
4 - + 
4 - + 
4 - + 
4 - + 
4 - + 
4 - + 
4 - + 
4 - + 
4 - + 
4 - + 
(-) negative staining 
(+) positive staining 
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Figure 3.12 Caspase-3 activity assay Primary mouse hepatocytes  were treated with TNF-
 (20ng/ml) or TGF- (5 ng/ml) with/without rDll4 (500 ng/ml) for 48 h. 
3.2.2 rDll4 did not impact HSCs activation 
Incubation of primary HSCs with rDll4 for 3 d did not change mRNA expression of 
Col11, Col12, and -Sma (Figure 3.13 A). Additionally, TGF-β-induced Col11 
and Col12 expression was not altered by rDll4 (Figure 3.13 B). Similar results were 
also obtained in JS-1 cell line (data not shown). 
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Figure 3.14 Effects of rDll4 on chemokines in KCs Primary KCs treated with LPS (20 n/ml) 
for 16 h with/without rDll4 (500 ng/ml) during the last 6 h of LPS treatment. mRNA levels of 
chemokines were quantified with qPCR. 
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4 DISCUSSION 
Previous studies reported the pivotal roles of Notch signaling in acute and chronic 
liver injuries (Bansal et al., 2015; Hoeft and Kramann, 2017; Yu et al., 2011; Zhang et 
al., 2016b). However, the roles of individual Notch ligands are still unknown. 
Underkoffler et al. found that Jag1 null mutant livers upregulated fibrosis-related 
genes (Underkoffler et al., 2013). However, Tang et al. showed that Jag1 knockdown 
diminished liver fibrosis by suppressing epithelial-mesenchymal transition (EMT) of 
HSCs in CCl4-treated rats (Tang et al., 2017).  
The current study investigated canonical Notch ligands and receptors in patients with 
hepatolithiasis and HBV-related cirrhosis. We focused on Notch ligands JAG1 and 
DLL4, the only ligands expressed in sinusoids of cirrhotic patients. IF staining 
identified KC and LSECs, but not HSCs, as the sinusoidal cells that express DLL4. 
The results suggest the potential association of the Notch ligand with liver 
inflammation, which was supported by additional data that sinusoidal DLL4 
expression correlated with inflammation grade in chronic HBV-infected patients 
(unpublished data).  
Under inflammatory conditions, expression of Notch ligands are induced by 
exogenous factors such as toll-like receptor (TLR) ligands (e.g. LPS) and pathogen 
(e.g. bacteria and virus) and endogenous inflammatory cytokines such as TNF-α and 
IL-1β (Shang et al., 2016). Fung and colleagues (2007) showed that human 
macrophages stimulated with LPS or interleukin (IL)1β increased the expression of 
DLL4. LPS also induced the expression of JAG1 in primary human and murine 
macrophages (Foldi et al., 2010). We found that LPS upregulated JAG1 expression, 
but did not affect DLL4, in RAW264.7 cells (Figure 10.3). This can be explained by 
different signaling kinetics of Notch family members. Previous studies reported earlier 
upregulation of JAG1 (12 h) compared to DLL4 (48 h) after LPS treatment of 
macrophages (Foldi et al., 2010; Fung et al., 2007). In the current experiment, we 
detected DLL4 and JAG1 24 h following LPS treatment. 
Besides Notch ligands, NOTCH1 receptor was overexpressed as well in the 
sinusoids of cirrhotic patients. The finding is consistent with a previous study showing 
that Notch1 mRNA was elevated 10-fold in livers of mice with HBV infection (Wei et 
al., 2016). In addition, the expression of the NOTCH1 receptor was altered as well in 
diverse inflammatory microenvironments (Briot et al., 2015; Fazio et al., 2016). 
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To understand the roles of JAG1 and DLL4 in liver injury, we examined the 
expression of the two Notch ligands in mice treated with CCl4. In contrast to patients, 
JAG1 or DLL4 were not expressed in sinusoids of the animals (data not shown). To 
observe the effects of DLL4 and JAG1 in this model, we injected recombinant DLL4 
and JAG1 into the animals. Several studies demonstrated the biological activity of 
recombinant Notch ligands in vivo. For examples, intraperitoneal injection of rDll4 
ameliorated acute kidney failure (Gupta et al., 2010). Following brain ischemia, rDll4 
increased expansion of neuronal progenitor cells together with other growth factors 
(Oya et al., 2008). 
In the CCl4 animal model, both rDll4 and rJag-1 improved liver fibrosis, reduced liver 
inflammation, and hepatocyte apoptosis. Next, we examined the effects of rDll4 and 
rJag-1 in BDL animals, additional classic liver injury and fibrosis model. Surprisingly, 
all BDL mice injected with Notch ligands died within 1 week while saline-treated BDL 
mice lived up to 2 weeks. Similar to Notch ligands, knockdown of A1 adenosine 
receptor decreased CCl4-induced fibrosis, whereas it increased fibrosis in BDL mice 
(Yang et al., 2010). Iwaisakoa et al. and Yang et al. reported different fibrosis-related 
genes between these two mouse models (Iwaisako et al., 2014; Yang et al., 2010). 
These results confirm the notion that these two animal models are different. On the 
other side, Notch signaling can induce opposite outcomes in different models of 
cellular proliferation, tumor growth, and organ fibrosis (Hoeft and Kramann, 2017; 
Schwanbeck et al., 2011). Taken together, disease etiology and cellular context 
determine the outcome of Notch signaling. 
Interestingly, blocking canonical Notch signaling pathway through specific KO of Rbjκ 
in myeloid cells improved fibrosis and diminished infiltration of macrophage and 
neutrophils cells in the liver of CCl4-and BDL-treated mice. On the contrary, general 
deletion of Rbjκ aggravated CCl4-induced hepatic fibrosis (He et al., 2015) 
highlighting the way of interference with Notch signaling as another determiner of the 
outcome of Notch signaling. 
To elucidate causes underlying BDL mice death, we analyzed liver tissues at early 
and late time points (6 h, 12 h, 24 h, 4 d, and 7 d) following BDL. We found that rDll4-
treated BDL mice had remarkable larger bile infarcts than BDL mice. Furthermore, 
enhanced bile infarct was accompanied by reduced inflammation. The absence of 
inflammation in rDll4-treated BDL mice facilitates the development of massive hepatic 
necrosis.   
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To clarify how rDll4 inhibited inflammatory cell infiltration, we examined the 
expression of chemokines in liver tissues and cultured cells. In vivo, rDll4 inhibited 
chemokine expression in both CCl4 and BDL treated mice. In vitro, rDll4 inhibited 
Ccl2, Ccl5, Ccl8, Cxcl9 in KCs, as well Ccl2 in HSCs.   
To test whether chemokine plays a crucial protective role in BDL mice, we treated the 
BDL mice with rCcl2. rCcl2 rescued rDll4-treated BDL mice from death. In rCcl2-
treated mice, inflammatory cells increased and size of bile infarcts reduced.  
The relationship between DLL4 and CCL2 has been studied in different disease 
settings by other groups. Aikawa and co-workers studied the interaction between 
DLL4 and CCL2 chemokines in macrophage RAW264.7 cells. In contrast to our 
findings, rDll4 increased Ccl2 expression in these cells, whereas Dll4 knockdown 
decreased Ccl2 expression. Similar results were also demonstrated in 3T3-L1 
adipocytes. Furthermore, anti-Dll4 antibody attenuated the expression of Ccl2 in 
atherosclerotic lesions (Fukuda et al., 2012). This difference might be explained by 
the experimental approaches. In the current study, we incubated macrophages with 
rDll4 directly, whereas Fukuda et al. immobilized rDll4 on the culture plate. 
Membrane-bound DLL4 and soluble DLL4 have different functional mechanisms as 
shown by previous studies (Lahmar et al., 2008). In addition, we investigated the 
impact of rDll4 on cells stimulated by LPS, whereas Fukuda et al. (2012) only 
examined rDll4 in the absence of LPS.  
To further investigate the mechanisms of how rDll4 inhibits CCL2, we focused on 
NFκB signaling pathway, the common downstream signaling exploited by 
inflammation (Ghosh and Hayden, 2008; Shang et al., 2016). The expression of p65 
protein, a primary effector of NFκB signaling pathway, increased in inflammatory cells 
infiltrating liver of BDL mice. Treatment with rDll4 decreased p65 expression in 
inflammatory cells. rCcl2 administration restored expression of p65. In RAW264.7 
cells, both rDll4 and NFκB inhibitor (JSH-23) inhibited LPS-induced CCL2 
expression. Furthermore, LPS-induced nuclear translocation of p65 was inhibited by 
rDll4 administration. These results suggest that rDll4 inhibits CCL2 expression 
through interfering with NFκB pathway. In line with our findings, Fukuda et al. also 
showed that CCL2 expression was increased in macrophages by DLL4 through 
NFκB pathway (Fukuda et al., 2012).  
Interestingly, inhibition of inflammation by rDll4 occurs in both CCl4 and BDL animal 
models. However, the Notch ligand produced opposite outcomes, which were 
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determined by different disease conditions. In the CCl4 model, rDll4-mediated 
chemokine inhibition decreases inflammatory cell infiltration and thus attenuates 
hepatocyte death and fibrosis. However, in the BDL model, limiting bile infarcts 
requires massive recruitment of inflammatory cells to clear the debris of dead liver 
cells. CCL2 inhibition by rDll4 blocks recruitment of circulating inflammatory cells into 
necrotic areas. Consequently, bile infarcts progress into massive hepatic necrosis.  
In addition to animal models, we found an inverse association between DLL4 and 
CCL2 expression in liver tissues of ACLF patients. ACLF is a new disease entity 
characterized by acute decompensation, dysregulated systemic inflammatory 
syndrome, and multiorgan failure. ACLF patients undergo systemic inflammatory 
response syndrome (SIRS) at the early stage of the disease. In such condition, 
patients suffered from cytokine storm characterized with extremely high levels of 
different pro-inflammatory cytokines, e.g. TNF-α, IL6, and chemokines including 
CCL2 (Alam et al., 2017; Khanam et al., 2017; Roth et al., 2009). CCL2 levels were 
increased in the serum and urine of ACLF patients (Graupera et al., 2016; Roth et al., 
2009). The absence of DLL4 expression might be a reason underlying high levels of 
CCL2 in ACLF. 
Several studies reported active Notch signaling in hepatic and extrahepatic 
inflammatory conditions including primary biliary cirrhosis (Shackel et al., 2001), 
rheumatoid arthritis (Park et al., 2015), systemic lupus erythematosus (Zhang et al., 
2010), and others (Shang et al., 2016). In addition, inhibition of DLL4 activity reduced 
inflammatory cells infiltration in several diseases (Fukuda et al., 2012; Takeichi et al., 
2010). On the other hand, myeloid Dll4 deficiency did not change the status of 
hepatic inflammation in low-density lipoprotein receptor KO (Ldlr-/-) mouse model of 
non-alcoholic steatohepatitis, (Jeurissen et al., 2016).  
In contrast to rDll4, rJag-1 did not affect Ccl2 expression in vitro and in vivo. rCcl2 did 
not protect rJag-1-treated BDL animals from death. Although the mechanisms of 
rJag-1-mediated effects remain highly speculative, it is clear that rJag-1-mediated 
responses are CCL2-independent. Moreover, rJag-1 did not influence LPS-induced 
Ccl2 expression or inhibit LPS-induced nuclear translocation of p50 and p65 in 
macrophages. The results suggest different functional mechanisms between rDll4 
and rJag-1, although they showed similar effects in BDL- and CCl4-induced liver 
injury. The difference is also reflected in the early changes of ALT and AST in BDL 
mice: rDll4 decreased, but rJag-1 increased serum ALT and AST levels. Additionally, 
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rJag-1 did not impact inflammatory cell infiltration in BDL mice compared to rDll4. 
Therefore, administration of rCcl2 did not benefit the BDL mice treated with rJag-1. 
By contrast, rCcl2 even led to larger massive bile infarcts than those of BDL mice 
only treated with rJag-1. 
 Co-IF analysis of macrophages further showed that rJag-1 increased LPS-induced 
p65 nuclear translocation in contrast to rDll4. Similarly, JAG1-NOTCH1 signaling 
increased several NFκB target genes in cultured endothelial cells (Nus et al., 2016). 
Considering that BDL mice have a higher sensitivity to LPS and NFκB signaling 
pathway (Harry et al., 1999), further potentiation of this signaling pathway by rJag-1 
might be responsible for the rapid death of BDL animals and the early increase in 
ALT and AST enzymes. Indeed, rJag-1 might increase bacterial translocation from 
intestine leading to an increase in the serum concentration of LPS thus accelerating 
the death of BDL mice. In this direction, previous studies already reported crucial 
roles for Notch signaling in intestinal homeostasis (Pellegrinet et al., 2011) and gut-
liver axis (Fowler et al., 2011). However, this interesting hypothesis is beyond the 
scope of the current study and merits further investigation to confirm it.  
The mechanistic differences between rDll4 and rJag-1 confirm the idea that Notch 
receptors and Notch ligands are not redundant. The same notion was confirmed by 
different animal phenotypes created by genetic modulation of these genes (Boucher 
et al., 2012). For example, DLL4 cannot replace DLL1 in myogenic differentiation 
(Preuße et al., 2015). Distinct biological functions were also reported for JAG1 versus 
JAG2 in cancer (Choi et al., 2009) and DLL1 versus JAG1 in osteoclastogenesis 
(Sekine et al., 2012). Similarly, DLL4 and JAG1 respond differently in various 
pathophysiological contexts. In plaques from patients with peripheral artery diseases, 
high expression of DLL4 was associated with upregulation of inflammatory genes 
such as CD68, COX2, and VCAM1. Under such conditions, JAG1 was 
downregulated and vice versa (Aquila et al., 2017).  
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individual members of Notch family will assist in the design of more effective Notch-
based therapeutics with minimal off-target effects.  
SUMMARY 
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5 SUMMARY 
Introduction 
To date, the roles of individual Notch ligands in liver injury are not well defined. The 
current study investigated whether and how Notch ligands DLL4 and JAG1 affect 
liver injury. 
Methods 
We examined the expression of Notch ligands and receptors by 
immunohistochemistry (IHC) in the liver samples of 26 patients with HBV-induced 
liver cirrhosis. The function of recombinant Dll4 (rDll4) and rJag-1 was investigated in 
vivo in carbon tetrachloride (CCl4) and bile duct ligation (BDL) animal models and in 
vitro in hepatocytes, Kupffer cells (KCs), and hepatic stellate cells (HSCs). 
Results 
DLL4 and JAG1 were the only Notch ligands expressed in liver sinusoids of 
examined patients. In the CCl4 animal model, rDll4 and rJag-1 ameliorated liver 
fibrosis, decreased infiltration of inflammatory cells, and inhibited apoptosis. On the 
contrary, rDll4 and rJag-1 caused rapid death of all BDL mice within 1 week. rDll4 
inhibited the expression of chemokine ligand 2 (CCL2) and infiltration of inflammatory 
cells in livers of BDL mice, whereas rJag-1 did not have any impact on inflammatory 
cells infiltration and CCL2 expression. In macrophages and HSCs, rDll4 inhibited 
LPS-induced CCL2 expression, whereas rJag-1 did not impact CCL2 expression. 
Inhibition of inflammation by rDll4 caused unrestricted bile infarct and rapid death of 
BDL animals. Recombinant Ccl2 (rCcl2) restored the infiltration of inflammatory cells, 
decreased the size of bile infarcts and rescued rDll4-treated BDL animals from death. 
In ACLF patients, DLL4 expression was negatively associated with expression of 
CCL2. In contrast to rDll4-treated BDL animals, rCcl2 did not rescue rJag-1-treated 
BDL animals.  
Conclusion 
Etiology determines the effects of DLL4  and JAG1 on liver injury. DLL4 inhibits liver 
inflammation through inhibiting CCL2, a key chemokine for recruitment of 
inflammatory cells. How Jag-1 impact liver injury requires further investigation. 
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10 APPENDIX 
10.1 Buffers / Solutions 
10.1.1 IHC 
10.1.1.1 EDTA retrieval solution 
EDTA (disodium salt) ..............................  0.37 g 
Distilled water to ..................................... 1000 mL 
Mix, adjust pH to 8.0 with 1N NaOH. 
10.1.1.2 Citrate retrieval solution 
Tri-sodium citrate (dihydrate)  ................. 2.94 g 
Distilled water to ..................................... 1000 mL 
Mix, adjust pH to 6.0 with 1N HCl, and add 0.5 mL of Tween 20. 
10.1.1.3 Picro-sirius red solution 
Sirius red (Sigma) ...................................  0.5 g 
Saturated aqueous solution of picric acid (Sigma) to ..............  500 mL 
10.1.1.4 Masson’s trichrome staining buffers 
Buffer A: 
Acid fuchsin ............................................ 0.5 g 
Ponceau Xylidine .................................... 0.5 g 
Distilled water ......................................... 99 mL 
Glacial acetic acid (Sigma-Aldrich) ......... 1 mL 
Buffer B: 
Phosphomolybdic acid (5%) ................... 25 mL 
Phosphotungstic acid (5%) ..................... 25 mL 
Buffer C: 
Light green .............................................. 2 g 
Glacial acetic acid (Sigma-Aldrich) ......... 2 mL 
Distilled water to ..................................... 100 mL 
Weigert's iron hematoxylin solution: 
Prepared according to Weigert by mixing equal parts of solution A and solution B 
(Table 2.1) 
10.1.2 IF/ICC 
10.1.2.1 BSA (3 %) 
Bovine serum albumin (Serve) ............... 15 g 
Distilled water to ..................................... 500 mL 
Mix well, add 250 µl Tween 20, aliquot and store at -20 C°. Thaw at RT before use. 
This buffer was used for blocking non-specific binding during IF staining. 
10.1.2.2 BSA (0.5 %)  
BSA ........................................................ 2.5 g 
Distilled water to ..................................... 500 mL 
Mix well, add 250 µl Tween 20 mL Tween 20, aliquot and store at -20 C°. Thaw at RT 
before use. This buffer was used for diluting primary and secondary antibodies during 
IF staining. 
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10.1.2.3 Wash buffer for ICC 
BSA ........................................................ 0.1 g 
PBS to .................................................... 100 mL 
Mix well and store at 4 C°. 
10.1.2.4 Blocking buffer for ICC 
BSA ........................................................ 1 g 
Triton-X-100 ............................................ 0.5 mL 
PBS to .................................................... 100 mL 
Mix well and store at 4 C°. 
10.1.3 ELISA 
10.1.3.1 Wash buffer 
 Weigh 9.55 g PBS powder for each liter. After dissolving in distilled water, adjust pH 
to 7.2-7.4, and filter solution through 0.22 µM filter. Then, add 0.5 mL Tween 20, mix 
the solution, and store at 4 C°. 
10.1.3.2 Diluent buffer 
BSA ........................................................ 10 g 
PBS (pH=7.2-7.4; 0.22 µM filtered) to..... 1000 mL 
Mix well, and store at 4 C°. 
10.1.4 Subcellular fractionation 
10.1.4.1 Harvest buffer 
HEPES 7.9 (100 mM) ............................. 5 mL 
NaCl (1 M) .............................................. 5 mL 
Sucrose .................................................. 8.56 g 
EDTA (10mM) ......................................... 0.5 mL 
Triton-X-100 ............................................ 250 µL 
DTT (1000 mM) ...................................... 50 µL 
Protease inhibitors .................................. 1 tablet 
Phosphatase inhibitors (100X) ................ 500 µL 
Distilled water to ..................................... 50 mL 
Mix well, aliquot, and store at -20 C°. 
10.1.4.2 Buffer A 
HEPES 7.9 (100 mM) ............................. 5 mL 
KCl (100 mM) ......................................... 5 mL 
EDTA (10 mM) ........................................ 0.5 mL 
EGTA (5 mM) ......................................... 1 mL 
DTT (1 M) ............................................... 50 µL 
Protease inhibitors .................................. 1 tablet 
Phosphatase inhibitors (100X) ................ 500 µL 
Distilled water to ..................................... 50 mL 
Mix well, aliquot, and store at -20 C°. 
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10.1.4.3 Buffer C 
HEPES 7.9 (100 mM) ............................. 5 mL 
NaCl (1 M) .............................................. 25 mL 
EDTA (10 mM) ........................................ 0.5 mL 
EGTA (5 mM) ......................................... 1 mL 
NP-40 ..................................................... 50 µL 
DTT (1 M) ............................................... 50 µL 
Protease inhibitors .................................. 1 tablet 
Phosphatase inhibitors (100X) ................ 500 µL 
Distilled water to ..................................... 50 mL 
Mix well, aliquot, and store at -20 C°. 
10.1.5 Immunoblotting 
10.1.5.1 Loading buffer 5x 
Β-Mercaptoethanol ................................. 2.5 mL 
SDS ........................................................ 2 g 
Bromo phenol blue ................................. 10 mg 
Tris HCl (Ph=6.8, 1M) ............................. 6 mL 
EDTA (500mM) ....................................... 200 µl 
Glycerin (99%) ........................................ 10 mL 
Distilled water  ........................................ 1.3 mL 
Mix well, aliquot and store at -20 C°. 
10.1.5.2 Gel composition 
Separating gel (12%) 
For preparing four gels, the following is added: 
Distilled water ......................................... 6 mL 
Acr-Bis (29:1) 30% ................................. 12 mL 
Tris (1M, pH=8.8) .................................... 11.4 mL 
SDS (10%) .............................................. 0.3 mL 
APS (10%) .............................................. 0.3 mL 
TEMED ................................................... 0.012 mL 
Stacking gel (5%) 
The mount needed to prepare four gels: 
Distilled water ......................................... 5.5 mL 
Acr-Bis (29:1) 30% ................................. 1.3 mL 
Tris (1M, pH=6.8) .................................... 1 mL 
SDS (10%) .............................................. 0.08 mL 
APS (10%) .............................................. 0.08 mL 
TEMED ................................................... 0.008 mL 
10.1.5.3 Running buffer 10x 
Glycine .................................................... 144 g 
Tris base ................................................. 30.34 g 
SDS (10% sol.) ....................................... 100 mL 
Distilled water to ..................................... 1000 mL 
10.1.5.4 Transfer buffer 10x 
Glycine .................................................... 144 g 
Tris base ................................................. 30.2 g 
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Distilled water to ..................................... 1000 mL 
For 1L (1X) transfer buffer solution, mix 100 mL transfer buffer (10x), 100 mL 
methanol, and 800 mL distilled water. 
10.1.5.5 TBS 10x buffer 
Tris base ................................................. 12.1 g 
NaCl........................................................ 87.66 g 
Distilled water to ..................................... 1000 mL 
Adjust pH to 7.6. For 1x TBST wash buffer, mix 100 mLl TBS buffer (10x), 900 mL 
distilled water, and 1 mL Tween 20. 
10.1.5.6 Enhanced chemiluminescence (ECL) solution 
Solution A 
TRIS buffer (0.1M, pH = 8,5) .................. 5 mL 
Luminol (250 mM) ................................... 50 µl 
p-coumaric acid (90 mM) ........................ 22 µl 
Solution B 
TRIS buffer (0.1M, pH = 8,5) .................. 5 mL 
H2O2 30 % (w/w) ..................................... 3 µl 
Mix solution A and B in equal ratio directly before use, incubate the washed 
membrane for 1 min in the ECL solution, dry the membrane and measure the 
luminescence. 
10.1.6 Activated caspase-3 assay 
Cell lysis buffer 
HEPES (100mM) .................................... 50 mL 
NaCl (750 mM) ....................................... 13.3 mL 
CHAPS ................................................... 0.1 g 
DTT (1 M) ............................................... 100 µL 
EDTA (100 mM) ...................................... 100 µL 
Distilled water to ..................................... 100 mL 
Assay buffer 
HEPES (100mM) .................................... 50 mL 
NaCl (750 mM) ....................................... 13.3 mL 
CHAPS ................................................... 0.1 g 
DTT (1 M) ............................................... 1 mL 
EDTA (100 mM) ...................................... 100 µL 
Glycerol .................................................. 10 mL 
Distilled water to ..................................... 100 mL 
10.1.7 Cell isolation 
10.1.7.1 Percoll solution 
To obtain density of 1,063 g/mL, mix 47.74 mL Easycoll® and 51.26 mL PBS in sterile 
250 ml flask according to the following formula: 
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10.1.7.9 MgSO4 .7 H2O solution 
MgSO4.7 H2O  ........................................ 1.23 g 
Distilled water to ..................................... 50 mL 
Mix and filter through 0.22 µm filter 
10.1.7.9 Amino acids solution 
L-Alanine ................................................ 0.27 g 
L-Aspartic Acid ....................................... 0.14 g 
L-Asparagine .......................................... 0.4 g 
L-Citrullin ................................................ 0.27 g 
L-Cysteine .............................................. 0.14 g 
L-Histidine ............................................... 1 g 
L-Glutamic Acid ...................................... 1 g 
L-Glycine ................................................ 1 g 
L-Isoleucine ............................................ 0.4 g 
L-Leucine ................................................ 0.8 g 
L-Lysine ..................................................  1.3 g 
L-Methionine ........................................... 0.55 g 
L-Ornithine .............................................. 0.65 g 
L-Phenylalanine ...................................... 0.55 g 
L-Proline ................................................. 0.55 g 
L-Serine ..................................................  0.65 g 
L-Threonine ............................................ 1.35 g 
L-Tryptophan .......................................... 0.65 g 
L-Tyrosine ............................................... 0.55 g 
L-Valine .................................................. 0.8 g 
Distilled water to ..................................... 1000 mL 
Mix, adjust pH to 7.6, filter through 0.22 µm filter, aliquot and store at -20 C°. 
10.1.7.10 Glutamine solution 
Glutamine ............................................... 0.07 g 
Distilled water to ..................................... 20 mL 
Mix and filter through 0.22 µm filter. Always prepare freshly. 
10.1.7.11 EDTA buffer 
Glucose solution ..................................... 124 mL 
KH buffer ................................................ 20 mL 
HEPES buffer 8.5 ................................... 20 mL 
Amino acids solution ............................... 30 mL 
Glutamine solution .................................. 2 mL 
EGTA solution ........................................ 0.8 mL 
Mix, warm at 37C° before infusion, and always prepare freshly. The amount can 
scaled up and down depending on the number of mice used for cells isolation. 
10.1.7.12 Collagenase buffer for HCs and KCs 
Glucose solution ..................................... 155 mL 
KH buffer ................................................ 25 mL 
HEPES buffer 8.5 ................................... 25 mL 
Amino acids solution ............................... 38 mL 
Glutamine solution .................................. 2.5 mL 
CaCl2.2 H2O solution .............................. 10 mL 
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Dissolve collagenase (18675 IU) in 40 mL collagenase buffer, filter and complete to 
130 mL with collagenase buffer, warm at 37C° before infusion, and always prepare 
freshly. The amount can be scaled up and down depending on the number of mice 
used for cells isolation. 
10.1.7.13 Suspension buffer for HCs 
Glucose solution ..................................... 310 mL 
KH buffer ................................................ 50 mL 
Amino acids solution ............................... 75 mL 
Glutamine solution .................................. 5 mL 
CaCl2.2 H2O solution .............................. 4 mL 
HEPES buffer 7.6 ................................... 50 mL 
MgSO4.7H2O solution ............................. 2 mL 
BSA ........................................................ 1 g 
Mix, and store at 4 C°. The amount can be scaled up and down depending on the 
number of mice used for cell isolation. 
10.1.7.14 HSCs isolation buffers 
 
EGTA Buffer 
NaCl........................................................ 8 g             
KCl  ......................................................... 400 mg           
NaH2PO4. H2O ........................................ 88.17 mg         
Na2HPO4 ................................................ 120.45 mg          
HEPES ................................................... 2380 mg                
NaHCO3 .................................................. 350 mg              
EGTA ...................................................... 190 mg                
Glucose .................................................. 900 mg   
Distilled water to ..................................... 1000 mL                
Collagenase buffer 
NaCl........................................................ 8 g             
KCl  ......................................................... 400 mg           
NaH2PO4. H2O ........................................ 88.17 mg         
Na2HPO4 ................................................ 120.45 mg          
HEPES ................................................... 2380 mg                
NaHCO3 .................................................. 350 mg                           
CaCl2. 2H2O............................................ 560 mg 
Distilled water TO ................................... 1000 mL                
GBSS/A (Gey’s balanced salt solution) 
KCl .......................................................... 370 mg               
MgCl2. 6H2O ........................................... 210 mg                  
MgSO4. 7H2O ......................................... 70 mg                   
Na2HPO4 ................................................ 59.6 mg                
KH2PO4 ................................................... 30 mg                 
Glucose .................................................. 991 mg                  
NaHCO3 .................................................. 2270 mg                
CaCl2. 2H2O............................................ 225 mg                  
Distilled water to ..................................... 1000 mL 
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Nycodenz solution 
Nycodenz ................................................ 32 g 
GBSS/A to .............................................. 110 mL 
Mix well, filter through o.22 µm, and store at 4C°. Adjust pH to 7.38 before use.  
Pronase solution 
Pronase E ............................................... 90 mg 
Collagenase buffer ................................. 150 mL 
Adjust pH to 7.38 before use: 
Collagenase D solution 
Collagenase D ........................................ 63 mg 
Collagenase buffer ................................. 200 mL 
Adjust pH to 7.38 before use. 
Stirring solution 
Collagenase D ........................................ 50 mg 
Pronase E ............................................... 50 mg 
Collagenase buffer ................................. 100 mL 
DNase (1mg/mL)  ................................... 200 µL  
Adjust pH to 7.38 before use. 
10.2 Mediums 
Table 10.1 Culture mediums and conditions 
Cells Medium 
Primary cells 
Hepatocytes Medium 1: William E, 10% FBS, 2mM L-
Glutamine (Glut), penicillin/streptomycin 
(P/S) (100 U/ml and 0.1 mg/ml 
respectively), and Dexamethasone (10-7 
M). Used for the first 4 h after cells 
seeding to help cell attachment, then 
replaced by medium 2 for another 4 h. 
Medium 2: as medium 1 but without FBS 
Medium 3: as medium 2 but without 
Dexamethasone. The cells were treated 
in medium 3. 
 
Hepatic stellate cells Growth medium: DMEM high glucose, 
10 % FBS, 2mM L-Glut, and P/S (100 
U/ml and 0.1 mg/ml respectively). 
Starvation medium: same as growth 
medium but without FBS 
 
Kupffer cells Growth medium: DMEM high glucose, 
10 % FBS, 2mM L-Glut, and P/S (100 
U/ml and 0.1 mg/ml respectively). 
Starvation medium: same as growth 
medium but without FBS 
 
Cell lines 
JS-1 (mouse HSC) Growth medium: DMEM high glucose, 
10 % FBS, 2mM L-Glut, and P/S (100 


